US20170370906A1 - Bioanalytical analysis of site-specific antibody drug conjugates - Google Patents
Bioanalytical analysis of site-specific antibody drug conjugates Download PDFInfo
- Publication number
- US20170370906A1 US20170370906A1 US15/606,304 US201715606304A US2017370906A1 US 20170370906 A1 US20170370906 A1 US 20170370906A1 US 201715606304 A US201715606304 A US 201715606304A US 2017370906 A1 US2017370906 A1 US 2017370906A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- adc
- drug
- protein
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC*F.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CC(C(=O)O)[C@@H](O)C1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(C)C)C(C)C Chemical compound CC*F.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CC(C(=O)O)[C@@H](O)C1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(C)C)C(C)C 0.000 description 7
- ZERUMVYVJOAZEW-JZVKYIDCSA-N [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6CC(=C)C[C@@]6([H])[C@H](O)N(C(C)C)C5=C4)=C3)C(=O)N1CC(=C)C2 Chemical compound [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6CC(=C)C[C@@]6([H])[C@H](O)N(C(C)C)C5=C4)=C3)C(=O)N1CC(=C)C2 ZERUMVYVJOAZEW-JZVKYIDCSA-N 0.000 description 2
- WKPWGQKGSOKKOO-SIBNOYASSA-N CC(C(OC(CC(N(C)c(cc(C/C(/C)=C/C=C/C(C(C1)(N2)O)OC)cc3OC)c3Cl)=O)C3(C)OC3C(C)C1OC2=O)=O)N(C)C(C)=O Chemical compound CC(C(OC(CC(N(C)c(cc(C/C(/C)=C/C=C/C(C(C1)(N2)O)OC)cc3OC)c3Cl)=O)C3(C)OC3C(C)C1OC2=O)=O)N(C)C(C)=O WKPWGQKGSOKKOO-SIBNOYASSA-N 0.000 description 1
- MFCQCUHPIUKWAY-UHFFFAOYSA-N CC(C)C(=O)CCCCCN1C(=O)CC(C(C)C)C1=O.CC(C)C(=O)CCN1C(=O)CC(C(C)C)C1=O.CC(C)CC(=O)NCCCCCC(=O)C(C)C.[H]N(CCOCCOCC(=O)C(C)C)C(=O)CCN1C(=O)CC(C(C)C)C1=O Chemical compound CC(C)C(=O)CCCCCN1C(=O)CC(C(C)C)C1=O.CC(C)C(=O)CCN1C(=O)CC(C(C)C)C1=O.CC(C)CC(=O)NCCCCCC(=O)C(C)C.[H]N(CCOCCOCC(=O)C(C)C)C(=O)CCN1C(=O)CC(C(C)C)C1=O MFCQCUHPIUKWAY-UHFFFAOYSA-N 0.000 description 1
- BQOWCLYQRUEYRE-BDSXQHABSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](C)[C@@H](O)C1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](C)[C@@H](O)C1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(C)C)C(C)C BQOWCLYQRUEYRE-BDSXQHABSA-N 0.000 description 1
- YBWYQDVJDLJQCP-KUEBVBRISA-N COC1=CC=CC2=C1C(=O)C1=C(C2=O)C(O)=C2C[C@@](O)(C(=O)C(C)C)C[C@H](O[C@H]3C[C@H]4[C@H](O[C@@H]5[C@@H](OC)OCCN45)[C@H](C)O3)C2=C1O Chemical compound COC1=CC=CC2=C1C(=O)C1=C(C2=O)C(O)=C2C[C@@](O)(C(=O)C(C)C)C[C@H](O[C@H]3C[C@H]4[C@H](O[C@@H]5[C@@H](OC)OCCN45)[C@H](C)O3)C2=C1O YBWYQDVJDLJQCP-KUEBVBRISA-N 0.000 description 1
- OTTJKZMMPDDHAP-XVYZUBRFSA-N COC1=CC=CC2=C1C(=O)C1=C(C2=O)C(O)=C2C[C@@](O)(C(=O)NCCSSC)C[C@H](O[C@H]3C[C@H]4[C@H](O[C@@H]5[C@@H](OC)OCCN45)[C@H](C)O3)C2=C1O Chemical compound COC1=CC=CC2=C1C(=O)C1=C(C2=O)C(O)=C2C[C@@](O)(C(=O)NCCSSC)C[C@H](O[C@H]3C[C@H]4[C@H](O[C@@H]5[C@@H](OC)OCCN45)[C@H](C)O3)C2=C1O OTTJKZMMPDDHAP-XVYZUBRFSA-N 0.000 description 1
- UJJJWTFCXKXVRP-TTYMQJSDSA-N COC1=CC=CC2=C1C(=O)C1=C(C2=O)C(O)=C2C[C@@](O)(C(=O)NCCSSC3=NC=CC=C3)C[C@H](O[C@H]3C[C@H]4[C@H](O[C@@H]5[C@@H](OC)OCCN45)[C@H](C)O3)C2=C1O Chemical compound COC1=CC=CC2=C1C(=O)C1=C(C2=O)C(O)=C2C[C@@](O)(C(=O)NCCSSC3=NC=CC=C3)C[C@H](O[C@H]3C[C@H]4[C@H](O[C@@H]5[C@@H](OC)OCCN45)[C@H](C)O3)C2=C1O UJJJWTFCXKXVRP-TTYMQJSDSA-N 0.000 description 1
- DPQLTFGXDVYSSL-XVQJQKMBSA-N [H]N1C(=O)OC2CC1(O)C(CO)/C=C/C=C(\C)CC1=CC(CO)=C(Cl)C(=C1)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CSC(C)C)C1(C)OC1C2C Chemical compound [H]N1C(=O)OC2CC1(O)C(CO)/C=C/C=C(\C)CC1=CC(CO)=C(Cl)C(=C1)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CSC(C)C)C1(C)OC1C2C DPQLTFGXDVYSSL-XVQJQKMBSA-N 0.000 description 1
- VLUFRJTWIQUKGD-RSIGIMFHSA-N [H]N1C(=O)O[C@H]2C[C@]1(O)[C@H](CO)/C=C/C=C(\C)CC1=CC(CO)=C(Cl)C(=C1)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SC(C)C)[C@]1(C)O[C@H]1[C@@H]2C.[H]N1C(=O)O[C@H]2C[C@]1(O)[C@H](CO)/C=C/C=C(\C)CC1=CC(CO)=C(Cl)C(=C1)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCC([H])(C)SC(C)C)[C@]1(C)O[C@H]1[C@@H]2C.[H]N1C(=O)O[C@H]2C[C@]1(O)[C@H](CO)/C=C/C=C(\C)CC1=CC(CO)=C(Cl)C(=C1)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSC(C)C)[C@]1(C)O[C@H]1[C@@H]2C Chemical compound [H]N1C(=O)O[C@H]2C[C@]1(O)[C@H](CO)/C=C/C=C(\C)CC1=CC(CO)=C(Cl)C(=C1)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SC(C)C)[C@]1(C)O[C@H]1[C@@H]2C.[H]N1C(=O)O[C@H]2C[C@]1(O)[C@H](CO)/C=C/C=C(\C)CC1=CC(CO)=C(Cl)C(=C1)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCC([H])(C)SC(C)C)[C@]1(C)O[C@H]1[C@@H]2C.[H]N1C(=O)O[C@H]2C[C@]1(O)[C@H](CO)/C=C/C=C(\C)CC1=CC(CO)=C(Cl)C(=C1)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSC(C)C)[C@]1(C)O[C@H]1[C@@H]2C VLUFRJTWIQUKGD-RSIGIMFHSA-N 0.000 description 1
- JHJBJUACTPYALD-KNILQROTSA-N [H]N1C(=O)O[C@H]2C[C@]1(O)[C@H](CO)/C=C/C=C(\C)CC1=CC(CO)=C(Cl)C(=C1)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CSC)[C@]1(C)O[C@H]1[C@@H]2C Chemical compound [H]N1C(=O)O[C@H]2C[C@]1(O)[C@H](CO)/C=C/C=C(\C)CC1=CC(CO)=C(Cl)C(=C1)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CSC)[C@]1(C)O[C@H]1[C@@H]2C JHJBJUACTPYALD-KNILQROTSA-N 0.000 description 1
- ZZYQCHCXERFGLD-DMMFXARYSA-N [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6C=C(/C=C/C)C[C@@]6([H])C(O)N(C(C)C)C5=C4)=C3)C(=O)N1C=C(/C=C/C)C2 Chemical compound [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6C=C(/C=C/C)C[C@@]6([H])C(O)N(C(C)C)C5=C4)=C3)C(=O)N1C=C(/C=C/C)C2 ZZYQCHCXERFGLD-DMMFXARYSA-N 0.000 description 1
- PRUJXRFFBDYLQL-IJXXKSAISA-N [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6C=C(C)C[C@@]6([H])C(O)N(C(C)C)C5=C4)=C3)C(=O)N1C=C(C)C2 Chemical compound [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6C=C(C)C[C@@]6([H])C(O)N(C(C)C)C5=C4)=C3)C(=O)N1C=C(C)C2 PRUJXRFFBDYLQL-IJXXKSAISA-N 0.000 description 1
- ZERUMVYVJOAZEW-IJXXKSAISA-N [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6CC(=C)C[C@@]6([H])C(O)N(C(C)C)C5=C4)=C3)C(=O)N1CC(=C)C2 Chemical compound [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6CC(=C)C[C@@]6([H])C(O)N(C(C)C)C5=C4)=C3)C(=O)N1CC(=C)C2 ZERUMVYVJOAZEW-IJXXKSAISA-N 0.000 description 1
- LLVZIPJYRBDPRE-NWJGCQPWSA-N [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6CC(=CC)C[C@@]6([H])C(O)N(C(C)C)C5=C4)=C3)C(=O)N1CC(=CC)C2 Chemical compound [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6CC(=CC)C[C@@]6([H])C(O)N(C(C)C)C5=C4)=C3)C(=O)N1CC(=CC)C2 LLVZIPJYRBDPRE-NWJGCQPWSA-N 0.000 description 1
- CQBAQLDGSFRFLZ-IJXXKSAISA-N [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6CC(C)=C[C@@]6([H])C(O)N(C(C)C)C5=C4)=C3)C(=O)N1CC(C)=C2 Chemical compound [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=C(OC)C=C5C(=O)N6CC(C)=C[C@@]6([H])C(O)N(C(C)C)C5=C4)=C3)C(=O)N1CC(C)=C2 CQBAQLDGSFRFLZ-IJXXKSAISA-N 0.000 description 1
- YJVIXPKPBZCQGE-NSIWXZONSA-N [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=CC5=C(C=C4OC)C(=O)N4CC(=C)C[C@@]4([H])[C@H](O)N5C(=O)OCC(C)SSC4=NC=CC=C4)=C3)C(=O)N1CC(=C)C2 Chemical compound [H][C@]12C=NC3=C(C=C(OC)C(OCCCCCOC4=CC5=C(C=C4OC)C(=O)N4CC(=C)C[C@@]4([H])[C@H](O)N5C(=O)OCC(C)SSC4=NC=CC=C4)=C3)C(=O)N1CC(=C)C2 YJVIXPKPBZCQGE-NSIWXZONSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Definitions
- This disclosure relates to methods of capturing, detecting, analyzing, characterizing, and quantifying antibody-drug conjugates, and their fragments and metabolites, in non-biological or biological matrices by chromatography and/or mass spectrometry.
- ADCs antibody drug conjugates
- ADCs are generally composed of an antibody, a pharmaceutically active small molecule drug or toxin (often referred to as the “drug moiety” or “payload”), and an optional linker to connect the two.
- This protein construct thus joins the small-molecule, highly potent drug to the large-molecule antibody, which is selected or engineered to target antigens on a specific cell type, typically a cancer cell.
- ADCs thus employ the powerful targeting ability of monoclonal antibodies to specifically deliver highly potent, conjugated small molecule therapeutics to a cancer cell.
- the small molecule therapeutic payload is often a highly-potent, cytotoxic molecule that would be too toxic for use in conventional chemotherapy.
- Liquid chromatography-tandem mass spectrometry is a powerful tool for protein analysis and quantitation in very complex matrices like plasma/serum/tissue samples. Since peptides resulting from the digestion of the protein of interest and other endogenous proteins may have the same or similar nominal mass, the second dimension of MS fragmentation often provides a unique fragment of a peptide of interest. The combination of the specific parent peptide and the unique fragment ion may be used to selectively monitor for the molecule to be quantified. Such approach is termed “Multiple reaction monitoring” (MRM), also referred to as Selected Reaction Monitoring (SRM), which is a commonly used mode for protein quantification. But this powerful tool may be compromised by the analysis of a complex mixture of intact ADCs, antibody fragments, and peptide-linked drug(s) as well as free drug molecules.
- MRM Multiple reaction monitoring
- SRM Selected Reaction Monitoring
- next generation ADCs have been focused on exploring technologies to produce homogenous ADCs with improved stability, pharmacokinetics (PK) and therapeutic index. New types of linkers and toxins with a variety of cytotoxic mechanisms are also being explored. These next generation ADCs may pose additional bioanalytical challenges due to the structural complexity of new payloads and associated complex biotransformations in vivo.
- affinity capture LC-MS has been used for drug-to-antibody ratio (DAR) and catabolite characterization of intact ADCs.
- DAR drug-to-antibody ratio
- the intact ADC affinity capture LC-MS assay employs PNGase F to remove N-glycans in the Fc region and thus reduce the complexity and heterogeneity of ADC mass spectra.
- the intact mass spectra of new ADCs are more complex and the sensitivity and resolution of the method may not be sufficient to elucidate some structural modifications and accurately characterize DAR distribution.
- LC-MS Affinity capture liquid chromatography-mass spectrometry
- DAR direct drug-to-antibody ratio
- ADCs antibody-drug conjugates
- An aspect of the invention is an analytical approach for antibody drug conjugates (ADCs), such as THIOMAB antibody-drug conjugates (TDCs), where the linker drugs are site-specifically conjugated in the Fab region.
- ADCs antibody drug conjugates
- TDCs THIOMAB antibody-drug conjugates
- the affinity capture LC-MS F(ab′)2 assay incorporates affinity capture of ADCs via binding to the Fab region, followed by on-bead IdeS digestion to remove the Fc domain specifically and uniformly.
- the resulting F(ab′)2 ( ⁇ 100 kDa) fragments contain the key ADC structural information, such as drug-to-antibody ratio and drug metabolism and are more readily analyzed by electrospray ionization LCMS than the intact ADC ( ⁇ 150 kDa).
- the reduced size of analytes results in improved mass spectral sensitivity and resolution.
- the reduced and optimized sample preparation time for example, rapid removal of the Fc fragment by IdeS digestion, minimizes possible assay artifacts of drug metabolism and skewed DAR profiles that may result from the prolonged incubation times (e.g., overnight enzymatic treatment for Fc deglycosylation).
- the affinity capture LC-MS F(ab′)2 assay provides more detailed and accurate information on ADC biotransformations in vivo, enabling analysis of low-dose, labile, and complex site-specific ADCs with linker-drug conjugated in the Fab region.
- An embodiment of the invention is a method employing anti-Fc capture and IgdE protease digestion of ADCs with site-specific conjugated drug moieties in the Fc region.
- Robust methods are provided to detect and quantify antibody protein concentration and antibody-conjugated drug quantity and structure characterization by digestion of the antibody and separation of the drug component of an ADC, followed by chromatographic and/or mass spectrophotometric analysis of the resulting composition of the combined released drug and peptides from the digested antibody.
- the methods of the invention utilize ADC fragments containing the drug moiety as surrogates for intact ADCs and therefore provide increased assay sensitivity and resolution.
- the new methods also minimize artifacts of drug metabolism and reduce potential biased response to certain drug-to-antibody ratio (DAR) species.
- DAR drug-to-antibody ratio
- Antibody and ADC analysis was previously conducted using limited proteolytic digestion by attempting to control the activity of endoproteinase Lys-C, or proteinase PNGase, followed by reverse-phase HPLC and mass spectrometry. These methods were found to be insufficient in the analysis of some next generation ADCs containing recombinantly-engineered, specific drug conjugation sites, due to limitations in sensitivity, resolution, and biased response to certain DAR species.
- ADCs that are labile, demanding much higher MS resolution and that have site specific conjugations to highly potent DNA damaging agents, which are typically administered in low doses, and are therefore in samples at low concentrations, demanding much higher sensitivity in the analytical techniques used to characterize the ADC composition and characterize the structure of metabolites that may be present in biological samples collected after administration of the ADC to a human or other test subject.
- the invention provides consistent, reliable, efficient, high-resolution and highly sensitive methods of assessing stability, post-translational and chemical modifications during production, formulation, storage, and administration during the development of site-specific ADCs by combining site specific and controlled proteolytic digestion matched with the analysis of homogenous and site specific ADC to reduce the size of the ADC analytes.
- the reduced size of analytes results in improved mass spectral sensitivity, and resolution, and the response difference observed with some intact DARs are reduced.
- the specific proteolytic digestion eliminates the need for overnight deglycosylation of the Fc carbohydrates. Additionally, rapid proteolytic digestion minimizes assay artifacts that may result from overnight enzymatic treatments.
- the affinity capture LC-MS F(ab′)2 assays of this disclosure provide more detailed and accurate information on ADC biotransformations in vivo, for the analysis of low-dose, labile, and complex site-specific ADCs with linker-drug conjugated in the Fab region, which may not be feasible using previous methods
- the invention provides methods of evaluating an ADC by digesting an ADC containing at least one drug moiety linked to an antibody at a recombinantly-engineered site with a protease that cleaves the ADC to form a digested ADC composition that includes at least one peptide fragment that is not linked to the drug moiety, and at least one peptide fragment that is linked to the drug moiety.
- the digested ADC composition is then analyzed by high performance liquid chromatography (HPLC) and/or mass spectrometry (MS) to detect at least one peptide fragment that is linked to the at least one drug moiety.
- HPLC high performance liquid chromatography
- MS mass spectrometry
- the recombinantly-engineered specific site of attachment of the drug moiety to the ADC may be a site selected from a cysteine amino acid residue, a selenocysteine amino acid residue, a glutamine amino acid residue, a non-naturally occurring amino acid residue, and a sugar-modified glycan residue.
- the ADC may be an IgG antibody.
- the antibody portion of the ADC may be an antibody fragment.
- the antibody portion of the ADC may be a human or humanized antibody.
- the ADC may be glycosylated or phosphorylated.
- the antibody portion of the ADC may specifically bind to one or more tumor-associated antigens or cell-surface receptors.
- the drug moiety may comprise at least one aromatic ring.
- exemplary drug moieties include peptides, polyamides, maytansinoids, dolastatins, auristatins, calicheamicins, pyrrolobenzodiazepine (PBD), PNU-159682, anthracyclines, duocarmycins, vinca alkaloids, taxanes, trichothecene, CC1065, duocarmycin, camptothecin, elinafide, antibiotics, fluorophores, radioisotopes, as well as stereoisomers, isosteres, metabolites, analogs or derivatives of these compounds.
- the drug moiety may also be linked to the antibody portion of the ADC through a linker.
- the protease utilized in these methods may be selected from an IdeS protease, an IdeZ protease, an IgdE protease, a SpeB protease, a gingipain protease, an endoglycosidase, and combinations thereof.
- the digestion procedure may comprise incubating the ADC with the protease at a temperature between about 20° C. and about 45° C., and typically includes incubating the ADC with the protease at a temperature of about 37° C.
- the digestion may also comprise incubating the ADC with the protease at a pH between about pH 5 and about pH 9, and typically includes incubating the ADC with the protease at a pH of about pH 7.
- the digestion may also comprise incubating the ADC with the protease for a time period between about 0.1 hour and about 48 hours, and typically includes incubating the ADC with the protease for a time period of about 1 hour.
- the analyzing may include at least one of RP-LC, RP-LC/MS, and LC-MS/MS analyses.
- the ADC prior to the digesting step, may be suspended in a matrix selected from a buffer, whole blood, serum, plasma, cerebrospinal fluid, saliva, urine, lymph, bile, feces, sweat, vitreous, tears, and tissue.
- the ADC is suspended in whole blood, serum, plasma, or tissue of a mammal selected from a human, a cynomolgus monkey, a rat, and a mouse.
- the ADC may therefore be enriched prior to the digesting step, by a technique selected from size exclusion chromatography, dialysis, selective precipitation, differential centrifugation, filtration, gel electrophoresis, liquid chromatography, reversed-phase chromatography, immunoprecipitation, SpinTrap columns including protein A and protein G, NHS and streptavidin iron or phosphorus or immobilized antibodies or lectin, paramagnetic beads, immuno-depletion, fractionation, solid phase extraction, phosphopeptide enrichment, polyacrylamide gel electrophoresis, and desalting.
- the ADC may be bound to an affinity capture media.
- the affinity capture media may include at least one of bead- or resin-supported Protein A/G, target antigen-paramagnetic bead capture media, anti-idiotypic antibodies, anti-Hu antibodies, and anti-drug antibodies.
- These analytical methods may include washing the ADC bound to the affinity capture media to reduce non-antibody proteins in contact with the ADC. These methods may also include dephosphorylating or deglycosylating the ADC bound to the affinity capture media.
- the step of digesting may also be carried out while ADC is bound to the affinity capture media. Alternatively, or additionally, the ADC may be eluted from the affinity capture media prior to the step of digesting the ADC.
- an antibody-conjugated drug concentration of the ADC is calculated from the analysis of the digested ADC composition.
- the average DAR of the ADC is calculated from the analysis of the digested ADC composition.
- a metabolite or catabolite structure may be determined from the analysis of the digested ADC composition.
- the protein concentration of the ADC may be calculated from the analysis of the digested ADC composition.
- the protein concentration is correlated with a peak area from an RP-LC and/or MS analysis of at least one Fc fragment from the digested ADC.
- the extinction coefficient of the ADC is calculated from the analysis of the digested ADC composition.
- the average DAR of the ADC, metabolite or catabolite structure(s), and the protein concentration of the ADC are obtained from an RP-LC and/or MS analysis of at least one Fc fragment from the digested ADC.
- FIG. 1 depicts antibody fragments generated with IdeS protease cleavage of a THIOMABTM drug conjugate (TDC) in which linker-drug is conjugated site-specifically to the F(ab).
- TDC THIOMABTM drug conjugate
- Linker-drug may be conjugated site-specifically to either the F(ab) or Fc.
- FIG. 2 provides a schematic illustration of the IdeS digestion, 2nd-generation affinity capture LC-MS.
- FIG. 3 shows a schematic illustration of PNGase F (1 st -generation) and IdeS (2 nd -generation) digestion and the advantages of the 2nd-generation affinity capture LC-MS assay of this disclosure.
- FIG. 7 shows linker-drug deconjugation (-LD) and PNGaseF digestion, 1st-generation analysis of a labile TDC, TDC-L1, from rat plasma.
- FIG. 8 shows linker-drug deconjugation (-LD) and IdeS digestion, 2nd-generation (1E-2) analysis of a labile TDC, TDC-L1, from rat plasma.
- -LD linker-drug deconjugation
- 1E-2 2nd-generation
- FIG. 8 shows linker-drug deconjugation (-LD) and IdeS digestion, 2nd-generation (1E-2) analysis of a labile TDC, TDC-L1, from rat plasma.
- Artificial partial drug decomposition (-PD) was minimized by the 2nd-generation affinity capture LC-MS assay (B). Partial drug decomposition didn't impact the potency of TDC-L1, leading to no change in DAR.
- FIG. 9 shows MS peaks obtained during characterization of complicated TDC catabolites in mouse plasma in vivo. Due to loss of 42 Da from the drug molecule, MS peaks of TDC-L2 catabolites were not resolved in PNGaseF digestion (1st-generation) affinity capture LC-MS assay. Partial drug decomposition (-PD, 43 Da) significantly impacted the potency of the example TDC-L2, leading to the reduction of DAR accordingly.
- FIG. 10 shows MS peaks obtained during characterization of complicated TDC catabolites in mouse plasma in vivo. Due to loss of 42 Da from the drug molecule, MS peaks of TDC-L2 catabolites were near baseline-resolved using the IdeS digestion (2nd-generation assay). Partial drug decomposition (-PD, 43 Da) significantly impacted the potency of the example TDC-L2, leading to the reduction of DAR accordingly.
- FIG. 11 shows an RP-LCMS analysis of a site-specific ADC digested with the IdeS proteolytic enzyme.
- the Fc/2 fragment elutes first and base-line resolves from drug containing F(ab′)2.
- the peak area of the antibody fragment that does not contain the linker-drug is then used to calculate protein concentration.
- FIG. 12 shows the deconvoluted mass spectrum of Fc/2 from the analysis of FIG. 11 .
- FIG. 13A shows a standard curve of Fc/2 peak area vs. concentration over a range of 0.5-20 mg/ml generated using Trastuzumab digested with IdeS protease.
- Protein concentration of TDCs site-specifically conjugated on the F(ab) can be determined using peak area of the Fc/2 of the TDC and the linear regression.
- Traditional ADCs conjugated on inter-chain disulfides can also be characterized using this method as the Fc/2 fragment is also without drug in these conjugates.
- FIG. 13B shows a standard curve of (F(ab′)2 peak area vs. concentration over a range of 0.5-20 mg/ml generated using Trastuzumab digested with IdeS protease. Protein concentration of TDCs site-specifically conjugated on the Fc can be determined using peak area of the F(ab′)2 of the TDC (Bottom curve) and the linear regression.
- FIG. 14 shows a concentration determination of trastuzumab site-specifically conjugated at engineered cysteine K149C with linker-drug on the F(ab) at engineered cysteine K149C.
- the concentration was determined using Fc/2 peak areas (3 replicates) and linear regression from the standard curve.
- FIG. 15 shows a concentration determination of trastuzumab site-specifically conjugated at engineered cysteine S400C with linker-drug on the Fc at engineered cysteine S400C.
- the concentration was determined using F(ab′)2 peak areas (3 replicates) and linear regression from the standard curve.
- FIG. 16 shows a concentration determination of trastuzumab with linker-drug conjugated on inter-chain disulfides. The concentration was determined using Fc/2 peak areas (3 replicates) and linear regression from the standard curve. As the Fc/2 fragment contains no hinge disulfides, it contains no linker-drug.
- FIG. 17 shows a correlation of 81 THIOMABTM drug conjugate concentration values obtained by the IdeS protease digest method of this disclosure or a bicinchoninic acid assay (BCA) protein assay.
- PDC PBD dimer drug, disulfide linker
- This disclosure is drawn to single measurement methods to detect and quantify antibody and drug components of antibody drug conjugates (ADCs) that robustly measure total antibody and antibody-conjugated drug quantity from a single sample preparation thereby providing drug to antibody ratio (DAR) calculation and significant time and resource savings.
- ADCs antibody drug conjugates
- biological sample is any component derived or separated from an animal and includes blood, plasma, serum, cells, urine, cerebrospinal fluid (CSF), milk, bronchial lavage, bone marrow, amniotic fluid, saliva, bile, vitreous, tears, or tissue.
- CSF cerebrospinal fluid
- bronchial lavage bone marrow, amniotic fluid, saliva, bile, vitreous, tears, or tissue.
- Digestive enzyme is an enzyme capable of cleaving or hydrolyzing peptides or proteins into fragments in either a specific or generic, random manner.
- a digestive enzyme can form a digested antibody sample from an antibody where the antibody is a component of a biological sample.
- Digestive enzymes include proteases such as trypsin, papain, pepsin, endoproteinase LysC, endoproteinase ArgC, staph aureus V8, chymotrypsin, Asp-N, Asn-C, PNGaseF, endoproteinase GluC, and LysN.
- antibody is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
- antibody fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
- antibody fragments include but are not limited to Fv, Fc, Fab, Fab′, Fab′-SH, F(ab′)2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.
- an antibody provided herein is an antibody fragment.
- Antibody fragments include, but are not limited to, Fab, Fab′, Fab′-SH, F(ab′)2, Fv, and scFv fragments, and other fragments described below.
- Fab fragment antigen
- Fab′ fragment antigen binding domain
- Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific (EP 404097; WO 1993/01161; Hudson et al. (2003) Nat. Med. 9:129-134; Hollinger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448). Triabodies and tetrabodies are also described in Hudson et al. (2003) Nat. Med. 9:129-134.
- Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
- a single-domain antibody is a human single-domain antibody (U.S. Pat. No. 6,248,516).
- Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.
- recombinant host cells e.g. E. coli or phage
- Fc region herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region.
- the term includes native sequence Fc regions and variant Fc regions.
- a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain.
- the C-terminal lysine (Lys447) of the Fc region may or may not be present.
- numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al. Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda Md. (1991), vols. 1-3.
- “Framework” or “FR” refers to constant domain residues other than hypervariable region (HVR) residues.
- the FR of a constant domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL):FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
- full length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
- a “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
- Human framework regions that may be used for humanization include but, are not limited to: framework regions selected using the “best-fit” method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (Carter et al. (1992) Proc. Natl. Acad. Sci. USA, 89:4285; Presta et al. (1993) J. Immunol., 151:2623); human mature (somatically mutated) framework regions or human germline framework regions (Almagro and Fransson, (2008) Front. Biosci.
- Human antibodies are described generally in van Dijk and van de Winkel, (2001) Curr. Opin. Pharmacol. 5:368-74; Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
- Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge.
- Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated.
- Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., (1991) J. Immunol., 147:86). Human antibodies generated via human B-cell hybridoma technology are also described in Li et al. (2006) Proc. Natl. Acad. Sci. USA, 103:3557-3502.
- Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.
- a “human consensus framework” is a framework region of an antibody which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences.
- the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences.
- the subgroup of sequences is a subgroup, as in Kabat et al. supra.
- the subgroup is subgroup kappa I.
- the subgroup III is subgroup III.
- a “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs.
- a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody.
- a humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody.
- a “humanized form” of an antibody, e.g., a non-human antibody refers to an antibody that has undergone humanization.
- chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
- An exemplary “chimeric” antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region (U.S. Pat. No. 4,816,567; Morrison et al. (1984) Proc. Natl. Acad. Sci. USA, 81:6851-6855).
- Another exemplary chimeric antibody is a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
- a chimeric antibody is a humanized antibody.
- a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody.
- a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences.
- HVRs e.g., CDRs, (or portions thereof) are derived from a non-human antibody
- FRs or portions thereof
- a humanized antibody optionally will also comprise at least a portion of a human constant region.
- some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.
- a non-human antibody e.g., the antibody from which the HVR residues are derived
- Antibodies of this disclosure may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., 2001) and further described, e.g., in McCafferty et al. (1990) Nature 348:552-554; Clackson et al., Nature 352:624-628 (1991); Marks et al. (1992) J. Mol. Biol.
- repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al. (1994) Ann. Rev. Immunol., 12:433-55.
- Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.
- scFv single-chain Fv
- naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self-antigens without any immunization as described by Griffiths et al., (1993) EMBO J, 12:725-734.
- naive libraries can also be made synthetically by cloning un-rearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter (1992) J. Mol. Biol., 227:381-388. Human antibody phage libraries are described in U.S. Pat. No.
- Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments for the purposes of this disclosure.
- An antibody may be a multispecific antibody, e.g. a bispecific antibody.
- Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. One of the binding specificities may be for one antigen while the other is for a second antigen.
- bispecific antibodies may bind to two different epitopes of the same antigen.
- Bispecific antibodies may also be used to localize cytotoxic agents to cells which express an antigen.
- Bispecific antibodies can be prepared as full length antibodies or antibody fragments (see, e.g., Ortiz-Sanchez et al., Expert Opin. Biol. Ther. (2008) 8(5):609-32).
- Multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, Nature 305:537 (1983)), WO 1993/08829, and Traunecker et al., EMBO J. 10:3655 (1991)), and “knob-in-hole” engineering (U.S. Pat. No. 5,731,168).
- Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No.
- Optus antibodies are also included herein (e.g. US 2006/0025576).
- the antibody or fragment herein also includes a “Dual Acting FAb” or “DAF” comprising an antigen binding site that binds to an antigen as well as another, different antigen (e.g., US 2008/0069820).
- DAF Double Acting FAb
- Amino acid sequence variants of the antibodies provided herein are also contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody.
- Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
- Antibodies include fusion proteins comprising an antibody and a protein, drug moiety, label, or some other group. Fusion proteins may be made by recombinant techniques, conjugation, or peptide synthesis, to optimize properties such as pharmacokinetics.
- the human or humanized antibodies may also be a fusion protein comprising an albumin-binding peptide (ABP) sequence (see, Dennis et al (2002) J Biol. Chem. 277:35035-35043 at Tables III and IV, page 35038; US Pat. Pub. No. 2004/0001827 at [0076]; and WO 01/45746 at pages 12-13, all of which are incorporated herein by reference).
- ABSP albumin-binding peptide
- Antibody variants having one or more amino acid substitutions are provided for use and analysis in the methods of this disclosure.
- Sites of interest for substitutional mutagenesis include the HVRs and FRs.
- Substantial changes are provided in the following table under the heading of “exemplary substitutions,” and are further described below in reference to amino acid side chain classes.
- Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved antibody-dependent cell-mediated cytotoxicity (ADCC) or CDC.
- ADCC antibody-dependent cell-mediated cytotoxicity
- Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
- substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody).
- a parent antibody e.g. a humanized or human antibody
- the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody.
- An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g. binding affinity).
- Alterations may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR “hotspots,” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, (2008) Methods Mol. Biol. 207:179-196), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity.
- HVR “hotspots” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, (2008) Methods Mol. Biol. 207:179-196), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity.
- Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom
- affinity maturation diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis).
- a secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity.
- Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.
- substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen.
- conservative alterations e.g., conservative substitutions as provided herein
- Such alterations may be outside of HVR “hotspots” or SDRs.
- each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.
- a useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells (1989) Science, 244:1081-85.
- a residue or group of target residues e.g., charged residues such as arg, asp, his, lys, and glu
- a neutral or negatively charged amino acid e.g., alanine or polyalanine
- Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions.
- a crystal structure of an antigen-antibody complex is used to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution.
- Variants may be screened to determine whether they contain the desired properties.
- Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
- terminal insertions include an antibody with an N-terminal methionyl residue.
- Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.
- an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated.
- Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.
- the carbohydrate attached thereto may be altered.
- Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region (Wright et al. (1997) TIBTECH 15:26-32).
- the oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure.
- modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.
- antibody variants having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region.
- the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65%, or from 20% to 40%.
- the amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e.g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry (see, e.g., WO 2008/077546).
- Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ⁇ 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function (U.S. Pat. Pub. Nos. 2003/0157108; US 2004/0093621).
- Patent publications describing “defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al. (2004) Biotech. Bioeng.
- Cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US 2003/0157108; and WO 2004/056312, especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (Yamane-Ohnuki, et al. (2004) Biotech. Bioeng. 87:614; Kanda, et al. (2006) Biotechnol. Bioeng., 94(4):680-688; WO2003/085107).
- Antibody variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Publications describing such antibody variants having bisected oligosaccharides include WO 2003/011878; U.S. Pat. No. 6,602,684; and US Pat. Pub. 2005/0123546. Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided and may have improved CDC function. Publications describing such galactose residue antibody variants include WO 1997/30087; WO 1998/58964; WO 1999/22764.
- ADC design one of the main challenges in ADC design is the homogeneity of currently available ADCs that may have zero to eight drug molecules linked to each antibody or antibody fragment.
- This heterogeneity in ADC species adversely influences analytical methods of evaluating and monitoring stability, consistency, pharmacokinetics, and in vivo performance of ADC compositions.
- conjugation strategies have been identified that permit chemical installation of the drug onto an antibody at pre-determined site(s), to ensure stability of the conjugate following production and, while in circulation, in vivo.
- site-specific ADCs also referred to as immunoconjugates
- THIOMAB-drug conjugates can be controlled to produce a homogeneous DAR2.
- Cysteine-engineered antibodies comprise one or more residues of an antibody substituted with cysteine residue(s).
- the substituted residues may occur at accessible sites of the antibody, such that reactive thiol groups are positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create a site-specific ADC.
- THIOMABs include cysteine engineered antibodies in which any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and 5400 (EU numbering) of the heavy chain Fc region, and S121, and K149 of the light chain.
- Methods of making cysteine engineered antibodies include, but are not limited to, the methods described in U.S. Pat. No. 7,521,541; U.S. Pat. No. 9,000,130.
- the methods of this disclosure may be applied to antibody-drug conjugates comprising cysteine engineered antibodies wherein one or more amino acids of a wild-type or parent antibody are replaced with a cysteine amino acid (THIOMABTM).
- THIOMABTM cysteine amino acid
- Any form of antibody may be so engineered.
- a parent Fab antibody fragment may be engineered to form a cysteine engineered Fab
- a parent monoclonal antibody may be engineered to form a cysteine engineered monoclonal antibody.
- a single site mutation yields a single engineered cysteine residue in a Fab antibody fragment, while a single site mutation yields two engineered cysteine residues in a full length antibody, due to the dimeric nature of the IgG antibody.
- thiol reactivity value is a relative, numerical term in the range of 0 to 1.0 and can be measured for any cysteine engineered antibody.
- Thiol reactivity values of cysteine engineered antibodies of the invention are in the ranges of 0.6 to 1.0; 0.7 to 1.0; or 0.8 to 1.0.
- Cysteine amino acids may be engineered at reactive sites in the heavy chain (HC) or light chain (LC) of an antibody and which do not form intrachain or intermolecular disulfide linkages (Junutula, et al. (2008) Nature Biotech., 26(8):925-932; Dornan et al (2009) Blood 114(13):2721-2729; U.S. Pat. No. 7,521,541; U.S. Pat. No. 7,723,485; WO2009/052249, Shen et al (2012) Nature Biotech., 30(2):184-191; Junutula et al (2008) J. Immuno. Methods 332:41-52).
- the engineered cysteine thiols may react with linker reagents or the linker-drug intermediates of the present invention which have thiol-reactive, electrophilic pyridyl disulfide groups to form ADC with cysteine engineered antibodies and the drug moiety.
- the specific location (i.e., site) of the drug moiety in these engineered ADCs can thus be designed, controlled, and known.
- the drug loading can therefore be controlled since the engineered cysteine thiol groups typically react with thiol-reactive linker reagents or linker-drug intermediates in high yield.
- Engineering an antibody to introduce a cysteine amino acid by substitution at a single site on the heavy or light chain gives two new cysteines on the symmetrical antibody.
- a drug loading (DAR) near 2 can be achieved, with nearly complete homogeneity in these site specific conjugated ADCs.
- UAAs unnatural amino acids
- a mutant protein encoded by a gene with the amber stop codon (TAG) at the site of the desired UAA may be expressed in cells, along with a corresponding orthogonal tRNA/aminoacyl-tRNA synthetase (aaRS) pair capable of installing the UAA at the amber stop codon site (see, e.g., Liu and Schultz (2010) Annu. Rev. Biochem. 79:413-44).
- TAG amber stop codon
- aaRS orthogonal tRNA/aminoacyl-tRNA synthetase
- coli UAA expression systems was p-acetylphenylalanine, chosen for the bioorthogonal reactivity of its ketone (Wang, et al., (2003) Proc. Natl. Acad. Sci. U.S.A. 100:56-61.).
- This unnatural amino acid was conjugated to an aminooxy-auristatin F, and the resulting trastuzumab antibody displayed superior pharmacokinetic properties in mice (Tian, et al., (2014) Proc. Natl. Acad. Sci. U.S.A. 111:1766-1771).
- This site-specific engineering methodology can be expanded to include more than one biorthogonal functional group into the protein.
- This approach may provide antibody-drug conjugates with a specific number of known unnatural amino acid substitutions that are easily and consistently conjugated to a therapeutic moiety, such as an anti-cancer drug, producing a very homogenous ADC composition with drug conjugation(s) limited to precisely designed and identified sites in the protein.
- Selenocysteine is a natural, but rare, amino acid that exists in all kingdoms of life as a component of selenoproteins, of which only 25 are currently known in mammals. Selenocysteine contains selenium in the place of sulfur, which makes it more reactive towards electrophiles in acidic conditions than cysteine. This chemical property was used to selectively couple maleimide- and iodoacetamide-containing agents to antibodies containing genetically engineered selenocysteine residues (Hofer, et al. (2009) Biochemistry 48:12047-57; Li, et al., (2014) Methods 65:133-38).
- Selenocysteine was used to conjugate fluorescent probes, biotin and biotin polyethylene glycol (biotin-PEG) to antibodies, resulting in the fully functional conjugates having specifically defined sites and stoichiometries of agent attachment, demonstrating the production of homogenous ADCs based on selenocysteine residue engineering. (see, e.g., Agarwal and Bertozzi, (2015) Bioconjugate Chem. 26:176-92; Sochaj, et al. (2015) Biotech. Advances 33:775-84).
- Human IgG molecules have a conserved glycosylation site at each N297 residue in the CH2 domain, making these pendant N-glycans a convenient target for site-specific conjugation. This glycosylation site is sufficiently far from the variable region that conjugation of drug moieties to attached glycans should not impact antigen binding.
- One method of linking therapeutic moieties to these glycans includes oxidative cleavage of the vicinal diol moieties contained in these glycans with periodate to generate aldehydes that can be reductively aminated and conjugated to hydrazide and aminooxy compounds (O'Shannessy, et al. (1984) Immunol. Lett. 8:273-77).
- Another method includes increasing the fucosylation of the N-acetylglucosamine residues in these glycans. Oxidation of these fucose residues produces carboxylic acid and aldehyde moieties that can be used to link drugs and fluorophores to these specific sites on the antibody (Zuberbuhler, et al. (2012) Chem. Commun. 48:7100-02).
- Another method includes modifying sialic acid in these glycans (as well as increasing the sialic acid content in these glycans) followed by oxidation of the sialic acid and conjugation with aminooxy-drugs to form oxime-linked conjugates (Zhou, et al. (2014) Bioconjugate Chem. 25:510-20).
- a sialyltransferase may be used to incorporate a modified sialic acid residue containing a bioorthogonal functional group into these glycans.
- the bioorthogonal functional group may then be modified to attach therapeutic moieties to the site of the glycan (Li, et al. (2014) Angew. Chem. Int. 53:7179-82).
- Another approach to modifying these glycan sites is the use of glycosyltransferases to link galactose, or galactose analogues containing ketones or azides, to the N-acetylglucosamine in these glycans, and linking drugs or radionucleotides to the galactose molecules (Khidekel, et al., (2003) J. Am. Chem. Soc. 125:16162-63; Clark, et al., (2008) J. Am. Chem. Soc. 130:11576-77; Boeggeman, et al. (2007) Bioconjugate Chem. 18:806-14).
- Probodies are recombinant, proteolytically-activated antibody prodrugs, comprised of a monoclonal antibody in which the amino terminus of the antibody light chain is extended with a protease-cleavable linker and a masking peptide designed to block antibody binding to an antigen (U.S. Pat. No. 8,563,269; Desnoyers, et al., Sci Transl Med. 2013 16;5(207):207ra144; Polu and Lowman, Expert Opin Biol Ther. 2014, 14(8):1049-53; Wong, et al., Biochimie. 2016 122:62-7).
- Cleavage of the linker by specific tumor-associated proteases leads to dissociation of the mask and release of an antibody competent to bind to antigen in the tumor.
- Probodies are designed to exploit the fundamental dysregulation of extracellular protease activity that exists within the tumor microenvironment, relative to healthy tissue, thereby binding only minimally to antigen in healthy tissue where there are insufficient active proteases present to remove the mask.
- the mask is removed by cleavage of the linker, and antigen binding proceeds.
- PDCs Probody Drug Conjugates
- Antibody drug conjugates are also formed using antibodies, or antibody fragments, linked to hydrophilic polymers or peptides that are comprised of natural amino acids, which can themselves be attached to therapeutic peptides, proteins or small therapeutic molecules.
- the polymer or peptide essentially serves as a linker between the antibody and the therapeutic moiety (drug), but this linker provides a means to attach multiple therapeutic moieties, thereby significantly increasing DAR for each ADC molecule.
- DAR of 14-18, or even higher are possible while maintaining the site-specific conjugation attributes of a site-specific ADC.
- Exemplary ADCs that include such peptide/polymer conjugates include ADCs linked to the XTENTM peptides conjugate (Amunix, Mountain View, Calif.) at specific, engineered amino acid residues in the light chain of the antibody, such as the cysteine-engineered antibodies described above. These peptides are substantially homogeneous polypeptides that are useful as conjugation partners to link to one or more payloads via a cross-linker reactant resulting in an XTEN-payload ADC conjugate.
- peptide linkers are polypeptides composed of non-naturally occurring, substantially non-repetitive sequences having a low degree, or no secondary or tertiary structure under physiologic conditions, and typically have from about 36 to about 3000 amino acids, of which the majority or the entirety are small hydrophilic amino acids with defined numbers of orthogonal pendant reactive groups conjugated to one or more molecules of a targeting moiety that serves as a ligand to a cell-surface receptor and one or more molecules of an effector drug (U.S. Pat. Pub. 2015/0037359).
- cytokine fusion proteins There are a broad variety of antibody-cytokine fusion proteins that have been developed as biopharmaceutical products and approved by the FDA for use as drugs in the United States. Most of these fusion proteins target tumor antigens with a protein construct in which different cytokines have been fused to full-length antibodies or their derivatives (see, e.g., Ortiz-Sanchez et al. (2008) Expert Opin. Biol. Ther. 8(5):609-32; Sochaj, et al. (2015) Biotechnology Advances 33:775-84). Each cytokine can be fused at the amino- or carboxy-terminus of the antibody depending on the structure of the cytokine and antibody, in order to conserve the biological activity of both components.
- Fc-fusion constructs are being developed for non-cancer clinical indications such as autoimmune conditions. These proteins may directly compete with antibodies that target self proteins.
- Fc-fusion protein constructs have been categorized into four groups based on ligand specificity (binding to one or multiple epitopes on a ligand molecule) and valency (stoichiometry of binding to ligand molecules): bivalent with single-ligand specificity; monovalent with multi-ligand specificity; multivalent with single-ligand specificity; and monovalent with single-ligand specificity.
- these site-specific, engineered immunoconjugates may retain the antigen binding capability of their wild type, parent antibody counterparts.
- the site-specific antibody conjugates are capable of binding, preferably specifically, to antigens.
- antigens include, for example, tumor-associated antigens (TAA), cell surface receptor proteins, and other cell surface molecules, transmembrane proteins, signaling proteins, cell survival regulatory factors, cell proliferation regulatory factors, molecules known or suspected to contribute functionally to tissue development or differentiation, lymphokines, cytokines, molecules involved in cell cycle regulation, molecules involved in vasculogenesis, and molecules known or suspected to contribute functionally to angiogenesis.
- TAA tumor-associated antigens
- the tumor-associated antigen may be a cluster differentiation factor (i.e., a CD protein).
- An antigen to which a cysteine engineered antibody is capable of binding may be a member of a subset of one of the above-mentioned categories, wherein the other subset(s) of said category comprise other molecules/antigens that have a distinct characteristic (with respect to the antigen of interest).
- the site specific antibody conjugates used in the methods of this disclosure include immunoconjugates useful in the treatment of cancer including, but not limited to, antibodies against cell surface receptors and tumor-associated antigens (TAA).
- TAA tumor-associated antigens
- Tumor-associated antigens are known in the art, and can be prepared for use in generating antibodies using methods and information which are well known in the art.
- TAA tumor-associated antigens
- researchers have sought to identify transmembrane or otherwise tumor-associated polypeptides that are specifically expressed on the surface of one or more particular type(s) of cancer cell as compared to on one or more normal, non-cancerous cell(s).
- tumor-associated polypeptides are more abundantly expressed on the surface of the cancer cells as compared to on the surface of the non-cancerous cells.
- the identification of such tumor-associated cell surface antigen polypeptides has given rise to the ability to specifically target cancer cells for destruction via antibody-based therapies.
- TAA tumor-associated antigens
- TAA (1)-(53) listed below Information relating to these antigens, which are known in the art, is listed below and includes names, alternative names, Genbank accession numbers, and primary reference(s), following nucleic acid and protein sequence identification conventions of the National Center for Biotechnology Information (NCBI). Nucleic acid and protein sequences corresponding to TAA (1)-(53) are available in public databases such as GenBank.
- Tumor-associated antigens targeted by antibodies include all amino acid sequence variants and isoforms possessing at least about 70%, 80%, 85%, 90%, or 95% sequence identity relative to the sequences identified in the cited references, or which exhibit substantially the same biological properties or characteristics as a TAA having a sequence found in the cited references.
- a TAA having a variant sequence generally is able to bind specifically to an antibody that binds specifically to the TAA with the corresponding sequence listed.
- BMPR1B bone morphogenetic protein receptor-type IB, Genbank accession no. NM_001203
- BMPR1B bone morphogenetic protein receptor-type IB, Genbank accession no. NM_001203
- WO2004063362 Claim 2
- WO2003042661 Claim 12
- US2003134790-A1 Page 38-39
- WO2002102235 Claim 13; Page 296
- WO2003055443 Page 91-92
- WO200299122 Example 2; Page 528-530
- WO2003029421 (Claim 6); WO2003024392 (Claim 2; FIG.
- NP_001194 bone morphogenetic protein receptor, type IB/pid NP_001194.1—Cross-references: MIM:603248; NP_001194.1; AY065994;
- NP_036581 six transmembrane epithelial antigen of the prostate.
- MPF MPF
- MSLN MSLN
- SMR megakaryocyte potentiating factor
- mesothelin Genbank accession no. NM_005823
- Yamaguchi N., et al Biol. Chem. 269 (2), 805-808 (1994), Proc. Natl. Acad. Sci. U.S.A. 96 (20):11531-11536 (1999), Proc. Natl. Acad. Sci. U.S.A. 93 (1):136-140 (1996), J. Biol. Chem.
- Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b, Genbank accession no. NM_006424) J. Biol. Chem. 277 (22):19665-19672 (2002), Genomics 62 (2):281-284 (1999), Feild, J. A., et al (1999) Biochem. Biophys. Res. Commun.
- Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B, Genbank accession no. AB040878) Nagase T., et al (2000) DNA Res.
- PSCA hlg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene, Genbank accession no. AY358628); Ross et al (2002) Cancer Res.
- ETBR Endothelin type B receptor, Genbank accession no. AY275463
- Nakamuta M. et al Biochem. Biophys. Res. Commun. 177, 34-39, 1991
- Ogawa Y. et al Biochem. Biophys. Res. Commun. 178, 248-255, 1991
- Arai H. et al Jpn. Circ. J. 56, 1303-1307, 1992
- Arai H. et al J. Biol. Chem. 268, 3463-3470, 1993
- Sakamoto A. Yanagisawa M., et al Biochem. Biophys. Res. Commun.
- MSG783 (RNF124, hypothetical protein FLJ20315, Genbank accession no. NM_017763); WO2003104275 (Claim 1); WO2004046342 (Example 2); WO2003042661 (Claim 12); WO2003083074 (Claim 14; Page 61); WO2003018621 (Claim 1); WO2003024392 (Claim 2; FIG. 93); WO200166689 (Example 6); Cross-references: LocusID:54894; NP_060233.2; NM_017763_1;
- STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein, Genbank accession no. AF455138) Lab. Invest. 82 (11):1573-1582 (2002)); WO2003087306; US2003064397 (Claim 1; FIG. 1); WO200272596 (Claim 13; Page 54-55); WO200172962 (Claim 1; FIG.
- TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4, Genbank accession no. NM_017636).
- TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4, Genbank accession no. NM_017636).
- Xu, X.Z. et al Proc. Natl. Acad. Sci. U.S.A. 98 (19):10692-10697 (2001), Cell 109 (3):397-407 (2002), J. Biol. Chem. 278 (33):30813-30820 (2003)); US2003143557 (Claim 4); WO200040614 (Claim 14; Page 100-103); WO200210382 (Claim 1; FIG.
- CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor, Genbank accession no. NP_003203 or NM_003212).
- CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs.73792 Genbank accession no. M26004).
- CD79b (CD79B, CD79 ⁇ , IGb (immunoglobulin-associated beta), B29, Genbank accession no. NM_000626 or 11038674). Proc. Natl. Acad. Sci. U.S.A. (2003) 100 (7):4126-4131, Blood (2002) 100 (9):3068-3076, Muller et al (1992) Eur. J. Immunol. 22 (6):1621-1625); WO2004016225 (Claim 2, FIG.
- FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein 1a), SPAP1B, SPAP1C, Genbank accession no. NM_030764, AY358130). Genome Res. 13 (10):2265-2270 (2003), Immunogenetics 54 (2):87-95 (2002), Blood 99 (8):2662-2669 (2002), Proc. Natl. Acad. Sci. U.S.A. 98 (17):9772-9777 (2001), Xu, M. J., et al (2001) Biochem. Biophys. Res. Commun.
- HER2 ErbB2, Genbank accession no. M11730) Coussens L., et al Science (1985) 230(4730):1132-1139); Yamamoto T., et al Nature 319, 230-234, 1986; Semba K., et al Proc. Natl. Acad. Sci. U.S.A. 82, 6497-6501, 1985; Swiercz J. M., et al J. Cell Biol. 165, 869-880, 2004; Kuhns J. J., et al J. Biol. Chem.
- NCA NCA (CEACAM6, Genbank accession no. M18728); Barnett T., et al Genomics 3, 59-66, 1988; Tawaragi Y., et al Biochem. Biophys. Res. Commun. 150, 89-96, 1988; Strausberg R. L., et al Proc. Natl. Acad. Sci. U.S.A.
- MDP DPEP1, Genbank accession no. BC017023
- WO2003016475 (Claim 1); WO200264798 (Claim 33; Page 85-87); JP05003790 (FIG. 6-8); WO9946284 (FIG. 9); Cross-references: MIM:179780; AAH17023.1; BC017023_1;
- IL20R ⁇ (IL20Ra, ZCYTOR7, Genbank accession no. AF184971); Clark H. F., et al Genome Res. 13, 2265-2270, 2003; Mungall A. J., et al Nature 425, 805-811, 2003; Blumberg H., et al Cell 104, 9-19, 2001; Dumoutier L., et al J. Immunol. 167, 3545-3549, 2001; Parrish-Novak J., et al J. Biol. Chem. 277, 47517-47523, 2002; Pletnev S., et al (2003) Biochemistry 42:12617-12624; Sheikh F., et al (2004) J.
- PSCA Prostate stem cell antigen precursor, Genbank accession no. AJ297436
- BAFF-R B cell-activating factor receptor, BLyS receptor 3, BR3, Genbank accession No. AF116456
- BAFF receptor/pid NP_443177.1- Homo sapiens.
- CD22 B-cell receptor CD22-B isoform, BL-CAM, Lyb-8, Lyb8, SIGLEC-2, FLJ22814, Genbank accession No. AK026467); Wilson et al (1991) J. Exp. Med. 173:137-146; WO2003072036 (Claim 1; FIG. 1); Cross-references: MIM:107266; NP_001762.1; NM_001771_1;
- CD79a (CD79A, CD79 ⁇ , immunoglobulin-associated alpha, a B cell-specific protein that covalently interacts with Ig beta (CD79B) and forms a complex on the surface with Ig M molecules, transduces a signal involved in B-cell differentiation), pI: 4.84, MW: 25028 TM: 2 [P] Gene Chromosome: 19q13.2, Genbank accession No. NP_001774.10); WO2003088808, US20030228319; WO2003062401 (Claim 9); US2002150573 (Claim 4, pages 13-14); WO9958658 (Claim 13, FIG. 16); WO9207574 (FIG. 1); U.S. Pat. No.
- CXCR5 Burkitt's lymphoma receptor 1, a G protein-coupled receptor that is activated by the CXCL13 chemokine, functions in lymphocyte migration and humoral defense, plays a role in HIV-2 infection and perhaps development of AIDS, lymphoma, myeloma, and leukemia); 372 aa, pI: 8.54 MW: 41959 TM: 7 [P] Gene Chromosome: 11q23.3, Genbank accession No. NP_001707.1); WO2004040000; WO2004015426; US2003105292 (Example 2); U.S. Pat. No. 6,555,339 (Example 2); WO200261087 (FIG.
- HLA-DOB Beta subunit of MHC class II molecule (Ia antigen) that binds peptides and presents them to CD4+T lymphocytes); 273 aa, pI: 6.56 MW: 30820 TM: 1 [P] Gene Chromosome: 6p21.3, Genbank accession No. NP_002111.1) Tonnelle et al (1985) EMBO J. 4(11):2839-2847; Jonsson et al (1989) Immunogenetics 29(6):411-413; Beck et al (1992) J. Mol. Biol. 228:433-441; Strausberg et al (2002) Proc. Natl. Acad.
- P2X5 Purinergic receptor P2X ligand-gated ion channel 5, an ion channel gated by extracellular ATP, may be involved in synaptic transmission and neurogenesis, deficiency may contribute to the pathophysiology of idiopathic detrusor instability
- 422 aa pI: 7.63, MW: 47206 TM: 1
- Gene Chromosome 17p13.3, Genbank accession No. NP_002552.2
- Le et al (1997) FEBS Lett. 418(1-2):195-199; WO2004047749; WO2003072035 (Claim 10); Touchman et al (2000) Genome Res.
- LY64 Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family, regulates B-cell activation and apoptosis, loss of function is associated with increased disease activity in patients with systemic lupus erythematosis); 661 aa, pI: 6.20, MW: 74147 TM: 1 [P] Gene Chromosome: 5q12, Genbank accession No.
- NP_005573.1 US2002193567; WO9707198 (Claim 11, pages 39-42); Miura et al (1996) Genomics 38(3):299-304; Miura et al (1998) Blood 92:2815-2822; WO2003083047; WO9744452 (Claim 8, pages 57-61); WO200012130 (pages 24-26);
- FcRH1 Fc receptor-like protein 1, a putative receptor for the immunoglobulin Fc domain that contains C2 type Ig-like and ITAM domains, may have a role in B-lymphocyte differentiation
- WO2003077836 WO200138490
- WO200138490 Claim 6, FIG. 18E-1-18-E-2
- Davis et al 2001) Proc. Natl. Acad. Sci USA 98(17):9772-9777; WO2003089624 (Claim 8); EP1347046 (Claim 1); WO2003089624 (Claim 7);
- IRTA2 Immunoglobulin superfamily receptor translocation associated 2, a putative immunoreceptor with possible roles in B cell development and lymphomagenesis; deregulation of the gene by translocation occurs in some B cell malignancies
- 977 aa, pI: 6.88 MW: 106468 TM 1 [P] Gene Chromosome: 1q21, Genbank accession No.
- TENB2 (TMEFF2, tomoregulin, TPEF, HPP1, TR, putative transmembrane proteoglycan, related to the EGF/heregulin family of growth factors and follistatin); 374 aa, NCBI Accession: AAD55776, AAF91397, AAG49451, NCBI RefSeq: NP_057276; NCBI Gene: 23671; OMIM: 605734; SwissProt Q9UIK5; Genbank accession No.
- PMEL17 (silver homolog; SILV; D12S53E; PMEL17; SI; SIL); ME20; gp100) BC001414; BT007202; M32295; M77348; NM_006928; McGlinchey, R. P. et al (2009) Proc. Natl. Acad. Sci. U.S.A. 106 (33), 13731-13736; Kummer, M. P. et al (2009) J. Biol. Chem. 284 (4), 2296-2306;
- TMEFF1 transmembrane protein with EGF-like and two follistatin-like domains 1; Tomoregulin-1); H7365; C9orf2; C9ORF2; U19878; X83961; NM_080655; NM_003692; Harms, P. W. (2003) Genes Dev. 17 (21), 2624-2629; Gery, S. et al (2003) Oncogene 22 (18):2723-2727;
- GDNF-Ra1 GDNF family receptor alpha 1; GFRA1; GDNFR; GDNFRA; RETL1; TRNR1; RET1L; GDNFR-alpha1; GFR-ALPHA-1
- Ly6E lymphocyte antigen 6 complex, locus E; Ly67, RIG-E, SCA-2, TSA-1
- NP_002337.1 NP_002346.2
- de Nooij-van Dalen A. G. et al (2003) Int. J. Cancer 103 (6), 768-774
- Zammit D. J. et al (2002) Mol. Cell. Biol. 22 (3):946-952;
- TMEM46 shisa homolog 2 (Xenopus laevis); SHISA2
- NP_001007539.1 NM_001007538.1
- Furushima K. et al (2007) Dev. Biol. 306 (2), 480-492
- Clark H. F. et al (2003) Genome Res. 13 (10):2265-2270;
- Ly6G6D lymphocyte antigen 6 complex, locus G6D; Ly6-D, MEGT1; NP_067079.2; NM_021246.2; Mallya, M. et al (2002) Genomics 80 (1):113-123; Ribas, G. et al (1999) J. Immunol. 163 (1):278-287;
- LGR5 leucine-rich repeat-containing G protein-coupled receptor 5; GPR49, GPR67
- NP_003658.1 NM_003667.2
- Salanti G. et al (2009) Am. J. Epidemiol. 170 (5):537-545; Yamamoto, Y. et al (2003) Hepatology 37 (3):528-533;
- RET ret proto-oncogene; MEN2A; HSCR1; MEN2B; MTC1; PTC; CDHF12; Hs.168114; RET51; RET-ELE1); NP_066124.1; NM_020975.4; Tsukamoto, H. et al (2009) Cancer Sci. 100 (10):1895-1901; Narita, N. et al (2009) Oncogene 28 (34):3058-3068;
- LY6K lymphocyte antigen 6 complex, locus K; LY6K; HSJ001348; FLJ35226; NP_059997.3; NM_017527.3; Ishikawa, N. et al (2007) Cancer Res. 67 (24):11601-11611; de Nooij-van Dalen, A. G. et al (2003) Int. J. Cancer 103 (6):768-774;
- GPR19 G protein-coupled receptor 19; Mm.4787; NP_006134.1; NM_006143.2; Montpetit, A. and Colltt, D. (1999) Hum. Genet. 105 (1-2):162-164; O'Dowd, B. F. et al (1996) FEBS Lett. 394 (3):325-329;
- GPR54 (KISS1 receptor; KISS1R; GPR54; HOT7T175; AXOR12); NP_115940.2; NM_032551.4; Navenot, J. M. et al (2009) Mol. Pharmacol. 75 (6):1300-1306; Hata, K. et al (2009) Anticancer Res. 29 (2):617-623;
- ASPHD1 aspartate beta-hydroxylase domain containing 1; LOC253982); NP_859069.2; NM 181718.3; Gerhard, D. S. et al (2004) Genome Res. 14 (10B):2121-2127;
- Tyrosinase (TYR; OCAIA; OCA1A; tyrosinase; SHEP3); NP_000363.1; NM_000372.4; Bishop, D. T. et al (2009) Nat. Genet. 41 (8):920-925; Nan, H. et al (2009) Int. J. Cancer 125 (4):909-917;
- TMEM118 ring finger protein, transmembrane 2; RNFT2; FLJ14627); NP ‘ 001103373.1; NM_001109903.1; Clark, H. F. et al (2003) Genome Res. 13 (10):2265-2270; Scherer, S. E. et al (2006) Nature 440 (7082):346-351;
- GPR172A G protein-coupled receptor 172A; GPCR41; FLJ11856; D15Ertd747e); NP_078807.1; NM_024531.3; Ericsson, T. A. et al (2003) Proc. Natl. Acad. Sci. U.S.A. 100 (11):6759-6764; Takeda, S. et al (2002) FEBS Lett. 520 (1-3):97-101;
- CD33 a member of the sialic acid binding, immunoglobulin-like lectin family, is a 67-kDa glycosylated transmembrane protein. CD33 is expressed on most myeloid and monocytic leukemia cells in addition to committed myelomonocytic and erythroid progenitor cells. It is not seen on the earliest pluripotent stem cells, mature granulocytes, lymphoid cells, or nonhematopoietic cells (Sabbath et al., (1985) J. Clin. Invest. 75:756-56; Andrews et al., (1986) Blood 68:1030-5). CD33 contains two tyrosine residues on its cytoplasmic tail, each of which is followed by hydrophobic residues similar to the immunoreceptor tyrosine-based inhibitory motif (ITIM) seen in many inhibitory receptors;
- ITIM immunoreceptor tyrosine-based inhibitory motif
- CLL-1 (CLEC12A, MICL, and DCAL2)
- CTL/CTLD C-type lectin-like domain
- CLL-1 has been shown to be a type II transmembrane receptor comprising a single C-type lectin-like domain (which is not predicted to bind either calcium or sugar), a stalk region, and a transmembrane domain and a short cytoplasmic tail containing an ITIM motif.
- an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available.
- the moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers.
- water soluble polymers include polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof
- Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
- the polymer may be of any molecular weight, and may be branched or unbranched.
- the number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
- Conjugates of an antibody and a non-proteinaceous moiety may be formed by selectively heating by exposure to radiation.
- the non-proteinaceous moiety of such conjugate may be a carbon nanotube (Kam et al. (2005) Proc. Natl. Acad. Sci. USA 102:11600-605).
- the radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the non-proteinaceous moiety to a temperature at which cells proximal to the antibody-non-proteinaceous moiety are killed.
- hypervariable region refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops (“hypervariable loops”).
- native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3).
- HVRs generally comprise amino acid residues from the hypervariable loops and/or from the “complementarity determining regions” (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition.
- CDRs complementarity determining regions
- Exemplary hypervariable loops occur at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, (1987) J. Mol. Biol. 196:901-917).
- Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 of L1, 50-56 of L2, 89-97 of L3, 31-35B of H1, 50-65 of H2, and 95-102 of H3 (Kabat numbering).
- CDRs generally comprise the amino acid residues that form the hypervariable loops.
- CDRs also comprise “specificity determining residues,” or “SDRs,” which are residues that contact antigen. SDRs are contained within regions of the CDRs called abbreviated-CDRs, or a-CDRs.
- Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 of L1, 50-55 of L2, 89-96 of L3, 31-35B of H1, 50-58 of H2, and 95-102 of H3 (Almagro and Fransson, (2008) Front. Biosci. 13:1619-1633). Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.
- an “isolated” antibody is one which has been separated from a component of its natural environment.
- an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) methods.
- electrophoretic e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
- chromatographic e.g., ion exchange or reverse phase HPLC
- the term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts.
- polyclonal antibody preparations typically include different antibodies directed against different determinants (epitopes)
- each monoclonal antibody within a monoclonal antibody preparation is directed against a single determinant on an antigen.
- the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci.
- naked antibody refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel or fluorophore.
- the naked antibody may be present in a pharmaceutical formulation.
- “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures.
- native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain.
- VH variable heavy domain
- VL variable region
- the light chain of an antibody may be assigned to one of two types, called kappa ( ⁇ ) and lambda ( ⁇ ), based on the amino acid sequence of its constant domain.
- An antibody provided herein may be a multispecific antibody, e.g. a bispecific antibody.
- the term “multispecific antibody” as used herein refers to an antibody comprising an antigen-binding domain that has polyepitopic specificity (i.e., is capable of binding to two, or more, different epitopes on one molecule or is capable of binding to epitopes on two, or more, different molecules).
- multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different antigen binding sites (such as a bispecific antibody).
- the first antigen-binding domain and the second antigen-binding domain of the multispecific antibody may bind the two epitopes within one and the same molecule (intramolecular binding).
- the first antigen-binding domain and the second antigen-binding domain of the multispecific antibody may bind to two different epitopes on the same molecule.
- the two different epitopes that a multispecific antibody binds are epitopes that are not normally bound at the same time by one monospecific antibody, such as e.g. a conventional antibody or one immunoglobulin single variable domain.
- the first antigen-binding domain and the second antigen-binding domain of the multispecific antibody may bind epitopes located within two distinct molecules (intermolecular binding).
- the first antigen-binding domain of the multispecific antibody may bind to one epitope on one molecule
- the second antigen-binding domain of the multispecific antibody may bind to another epitope on a different molecule, thereby cross-linking the two molecules.
- the antigen-binding domain of a multispecific antibody may comprise two VH/VL units, wherein a first VH/VL unit binds to a first epitope and a second VH/VL unit binds to a second epitope, wherein each VH/VL unit comprises a heavy chain variable domain (VH) and a light chain variable domain (VL).
- multispecific antibodies include, but are not limited to, full length antibodies, antibodies having two or more VL and VH domains, and antibody fragments (such as Fab, Fv, dsFv, scFv, diabodies, bispecific diabodies and triabodies, antibody fragments that have been linked covalently or non-covalently).
- a VH/VL unit that further comprises at least a portion of a heavy chain variable region and/or at least a portion of a light chain variable region may also be referred to as an “arm” or “hemimer” or “half antibody.”
- a hemimer may comprise a sufficient portion of a heavy chain variable region to allow intramolecular disulfide bonds to be formed with a second hemimer.
- a hemimer comprises a knob mutation or a hole mutation, for example, to allow heterodimerization with a second hemimer or half antibody that comprises a complementary hole mutation or knob mutation. Knob mutations and hole mutations are discussed below.
- a multispecific antibody provided herein may be a bispecific antibody.
- the term “bispecific antibody” as used herein refers to a multispecific antibody comprising an antigen-binding domain that is capable of binding to two different epitopes on one molecule or is capable of binding to epitopes on two different molecules.
- a bispecific antibody may also be referred to herein as having “dual specificity” or as being “dual specific.” Exemplary bispecific antibodies may bind both and any other antigen.
- One of the binding specificities may be for HER2 and the other is for CD3. See, e.g., U.S. Pat. No. 5,821,337.
- Bispecific antibodies may bind to two different epitopes of the same molecule.
- Bispecific antibodies may bind to two different epitopes on two different molecules.
- Bispecific antibodies may also be used to localize cytotoxic agents to cells which express cancer-associated antigens. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.
- Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, Nature 305:537 (1983), WO 93/08829, and Traunecker et al., EMBO J. 10:3655 (1991)), and “knob-in-hole” engineering (see, e.g., U.S. Pat. No. 5,731,168, WO2009/089004, US2009/0182127, US2011/0287009, Marvin and Zhu, Acta Pharmacol. Sin. (2005) 26(6):649-658, and Kontermann (2005) Acta Pharmacol. Sin., 26:1-9).
- KnH knock-into-hole
- a protuberance for example, a protuberance into one polypeptide and a cavity (hole) into the other polypeptide at an interface in which they interact.
- KnHs have been introduced in the Fc:Fc binding interfaces, CL:CH1 interfaces or VH/VL interfaces of antibodies (see, e.g., US 2011/0287009, US2007/0178552, WO 96/027011, WO 98/050431, Zhu et al., 1997, Protein Science 6:781-788, and WO2012/106587).
- KnHs drive the pairing of two different heavy chains together during the manufacture of multispecific antibodies.
- multispecific antibodies having KnH in their Fc regions can further comprise single variable domains linked to each Fc region, or further comprise different heavy chain variable domains that pair with similar or different light chain variable domains.
- KnH technology can also be used to pair two different receptor extracellular domains together or any other polypeptide sequences that comprises different target recognition sequences (e.g., including affibodies, peptibodies and other Fc fusions).
- knock mutation refers to a mutation that introduces a protuberance (knob) into a polypeptide at an interface in which the polypeptide interacts with another polypeptide.
- the other polypeptide has a hole mutation.
- hole mutation refers to a mutation that introduces a cavity (hole) into a polypeptide at an interface in which the polypeptide interacts with another polypeptide.
- the other polypeptide has a knob mutation.
- a “protuberance” refers to at least one amino acid side chain which projects from the interface of a first polypeptide and is therefore positionable in a compensatory cavity in the adjacent interface (i.e. the interface of a second polypeptide) so as to stabilize the heteromultimer, and thereby favor heteromultimer formation over homomultimer formation, for example.
- the protuberance may exist in the original interface or may be introduced synthetically (e.g., by altering nucleic acid encoding the interface). In some embodiments, a nucleic acid encoding the interface of the first polypeptide is altered to encode the protuberance.
- nucleic acid encoding at least one “original” amino acid residue in the interface of the first polypeptide is replaced with nucleic acid encoding at least one “import” amino acid residue which has a larger side chain volume than the original amino acid residue.
- the side chain volumes of the various amino residues are shown, for example, in Table 1 of US2011/0287009.
- a mutation to introduce a “protuberance” may be referred to as a “knob mutation.”
- Import residues for the formation of a protuberance may be naturally occurring amino acid residues selected from arginine (R), phenylalanine (F), tyrosine (Y) and tryptophan (W).
- Exemplary import residues are tryptophan or tyrosine.
- the original residue for the formation of the protuberance may have a small side chain volume, such as alanine, asparagine, aspartic acid, glycine, serine, threonine or valine.
- a “cavity” refers to at least one amino acid side chain which is recessed from the interface of a second polypeptide and therefore accommodates a corresponding protuberance on the adjacent interface of a first polypeptide.
- the cavity may exist in the original interface or may be introduced synthetically (e.g. by altering nucleic acid encoding the interface).
- nucleic acid encoding the interface of the second polypeptide is altered to encode the cavity.
- the nucleic acid encoding at least one “original” amino acid residue in the interface of the second polypeptide is replaced with DNA encoding at least one “import” amino acid residue which has a smaller side chain volume than the original amino acid residue. It will be appreciated that there can be more than one original and corresponding import residue.
- Import residues for the formation of a cavity may be naturally occurring amino acid residues selected from alanine (A), serine (S), threonine (T) and valine (V).
- An import residue may be serine, alanine or threonine.
- the original residue for the formation of the cavity has a large side chain volume, such as tyrosine, arginine, phenylalanine or tryptophan.
- a mutation to introduce a “cavity” may be referred to as a “hole mutation.”
- the protuberance is “positionable” in the cavity which means that the spatial location of the protuberance and cavity on the interface of a first polypeptide and second polypeptide respectively and the sizes of the protuberance and cavity are such that the protuberance can be located in the cavity without significantly perturbing the normal association of the first and second polypeptides at the interface.
- protuberances such as Tyr, Phe and Trp do not typically extend perpendicularly from the axis of the interface and have preferred conformations
- the alignment of a protuberance with a corresponding cavity may, in some instances, rely on modeling the protuberance/cavity pair based upon a three-dimensional structure such as that obtained by X-ray crystallography or nuclear magnetic resonance (NMR). This can be achieved using widely accepted techniques in the art.
- An exemplary knob mutation in an IgG1 constant region is T366W (EU numbering).
- Exemplary hole mutations in an IgG1 constant region may comprise one or more mutations selected from T366S, L368A and Y407V (EU numbering).
- An exemplary hole mutation in an IgG1 constant region may comprise T366S, L368A and Y407V (EU numbering).
- An exemplary knob mutation in an IgG4 constant region is T366W (EU numbering).
- An exemplary hole mutation in an IgG4 constant region may comprise one or more mutations selected from T366S, L368A, and Y407V (EU numbering).
- An exemplary hole mutation in an IgG4 constant region comprises T366S, L368A, and Y407V (EU numbering).
- Percent (%) amino acid sequence identity with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
- % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2.
- the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
- the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
- the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows: 100 times the fraction X/Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B.
- variable region refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
- the variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See for example, Kindt et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity.
- antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively (Portolano et al. (1993) J. Immunol. 150:880-887; Clarkson et al. (1991) Nature 352:624-628).
- Tumor-associated antigens are known in the art as provided in the list of exemplary TAAs provided above, and can prepared for use in generating human or humanized antibodies using methods and information which are well known in the art.
- TAA Tumor-associated antigens
- researchers have sought to identify transmembrane or otherwise tumor-associated polypeptides that are specifically expressed on the surface of one or more particular type(s) of cancer cell as compared to one or more normal non-cancerous cell(s). Often, such tumor-associated polypeptides are more abundantly expressed on the surface of the cancer cells as compared to on the surface of the non-cancerous cells.
- TAA tumor-associated cell surface antigen polypeptides
- the antibody components of the ADCs useful in the methods of this disclosure may be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567.
- Isolated nucleic acids encoding such antibodies described herein are provided. Such nucleic acids may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody).
- One or more vectors e.g., expression vectors
- a host cell comprising such nucleic acid is also provided.
- a host cell may comprise (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody.
- the host cell may be eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell).
- methods of making an antibody comprising culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
- nucleic acid encoding an antibody may be isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
- Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
- Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells.
- antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed.
- For expression of antibody fragments and polypeptides in bacteria see, e.g., U.S. Pat. No. 5,648,237; U.S. Pat. No. 5,789,199; U.S. Pat. No. 5,840,523; Charlton, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N. J., (2003), pp. 245-254, describing expression of antibody fragments in E. coli. ) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
- eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern (Gerngross, (2004) Nat. Biotech. 22:1409-1414; Li et al. (2006) Nat. Biotech. 24:210-215).
- Suitable host cells for the expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
- Plant cell cultures can also be utilized as hosts (U.S. Pat. No. 5,959,177; U.S. Pat. No. 6,040,498; U.S. Pat. No. 6,420,548; U.S. Pat. No. 7,125,978; U.S. Pat. No. 6,417,429, describing PLANTIBODIESTM technology for producing antibodies in transgenic plants).
- Vertebrate cells may also be used as hosts.
- mammalian cell lines that are adapted to grow in suspension may be useful.
- Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al. (1977, J. Gen Virol. 36:59); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, (1980) Biol. Reprod.
- myeloma cell lines such as Y0, NS0 and Sp2/0.
- myeloma cell lines such as Y0, NS0 and Sp2/0.
- Yazaki and Wu Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).
- the antibody components of an ADC may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.
- An antibody may be tested for its antigen binding activity, e.g., by known methods such as ELISA, Western blot, etc.
- Competition assays may also be used to identify an antibody that competes with another known antibody for binding to antigen.
- a competing antibody may bind to the same epitope (e.g., a linear or a conformational epitope) that is bound by the known antibody.
- epitope e.g., a linear or a conformational epitope
- Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) “Epitope Mapping Protocols,” in Methods in Molecular Biology, Vol. 66 (Humana Press, Totowa, N.J.).
- Exemplary antibodies forming the site-specific ADC may include, but are not limited to, trastuzumab, ocrelizumab, pertuzumab, anti-PD1, anti-PD-L1, anti-neuropilin-1, anti-MUC16, rituximab, anti-mesothelin, anti-LY6E, anti-STEAP1, anti-FcRH5, anti-CD22, anti-B7H4, anti-LGR5, anti-CD79b, and anti-Napi2b.
- Drug moieties which form the drug component of the ADC may be covalently attached to antibodies through a linker unit to form antibody-drug conjugates for targeted therapeutic effects.
- An exemplary embodiment of an ADC compound comprises an antibody (Ab) which targets, e.g., a tumor cell, cytotoxic or cytostatic drug moiety (D), and a linker moiety (L) that attaches Ab to D.
- the antibody is attached through the one or more amino acid residues, such as lysine and cysteine, by the linker moiety (L) to D; the composition having the Formula: Ab-(L-D) p , where p is 1 to about 20, or from about 2 to about 5.
- the number of drug moieties which may be conjugated via a reactive linker moiety to an antibody molecule may be limited by the number of cysteine residues, including free cysteine residues present in the antibody or which may be introduced by methods described herein, or native cysteines that form the interchain disulfide bonds of the antibody.
- the drug moiety (D) of an ADC may include any therapeutic compound, moiety or group, especially a group that has a cytotoxic or cytostatic effect.
- exemplary drug moieties may impart such cytotoxic and cytostatic effects by mechanisms including, but not limited to, tubulin binding, DNA binding or intercalation, and inhibition of RNA polymerase, protein synthesis, and topoisomerase.
- Some cytotoxic drugs tend to be inactive or less active when conjugated to large antibodies or protein receptor ligands.
- Exemplary drug moieties include, but are not limited to, a peptide (including therapeutic peptides comprising one or more non-natural amino acids, such as cyclic peptides, beta peptides, stables peptides, and cysteine knot peptides), a polyamide, a maytansinoid, dolastatin, auristatin, calicheamicin, pyrrolobenzodiazepine (PBD), PNU-159682, anthracycline, duocarmycin, vinca alkaloid, taxane, trichothecene, CC1065, duocarmycin, camptothecin, elinafide, an antibiotic including a rifamycin or rifamycin-analog, a fluorophore, a radioisotope, and stereoisomers, isosteres, analogs or derivatives thereof, including derivatives of these drugs that have cytotoxic activity.
- a peptide including therapeutic peptides comprising
- the Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.
- a human Fc region sequence e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region
- an amino acid modification e.g. a substitution
- the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious.
- In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities.
- Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcyR binding (hence likely lacking ADCC activity), but retains FcRn binding ability.
- NK cells express Fc(RIII only, whereas monocytes express Fc(RI, Fc(RII and Fc(RIII FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991).
- in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 (see, e.g. Hellstrom, I. et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc.
- non-radioactive assay methods may be employed (see, for example, ACTITM non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, Calif.; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, Wis.).
- Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
- ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998).
- C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402.
- a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J. Immunol.
- FcRn binding and in vivo clearance/half-life determinations can also be performed using methods known in the art (see, e.g., Petkova, S. B. et al., Int'l. Immunol. 18(12):1759-1769 (2006)).
- the antibody may comprise the following three mutations according to EU numbering: M252Y, S254T, and T256E (the “YTE mutation”) (U.S. Pat. No. 8,697,650; see also Dall'Acqua et al., Journal of Biological Chemistry 281 (33):23514-23524 (2006).
- the YTE mutation does not affect the ability of the antibody to bind to its cognate antigen.
- the YTE mutation may increase the antibody's serum half-life compared to the native (i.e., non-YTE mutant) antibody.
- the YTE mutation may increase the serum half-life of the antibody by 2- to 10-fold compared to the native (i.e., non-YTE mutant) antibody. See, e.g., U.S. Pat. No. 8,697,650; see also Dall'Acqua et al., Journal of Biological Chemistry 281 (33):23514-23524 (2006).
- the YTE mutant may provide a means to modulate ADCC activity of the antibody.
- the YTEO mutant may provide a means to modulate ADCC activity of a humanized IgG antibody directed against a human antigen. See, e.g., U.S. Pat. No. 8,697,650; see also Dall'Acqua et al., Journal of Biological Chemistry 281 (33):23514-23524 (2006).
- the YTE mutant may allow the simultaneous modulation of serum half-life, tissue distribution, and antibody activity (e.g., ADCC of an IgG antibody). See, e.g., U.S. Pat. No. 8,697,650; see also Dall'Acqua et al., Journal of Biological Chemistry (2006) 281 (33):23514-24.
- antibody activity e.g., ADCC of an IgG antibody.
- Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 according to EU numbering (U.S. Pat. No. 6,737,056).
- Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327 according to EU numbering, including the so-called “DANA” Fc mutant with substitution of residues 265 and 297 to alanine according to EU numbering (i.e., D265A and N297A according to EU numbering) (U.S. Pat. No. 7,332,581).
- the Fc mutant comprises the following two amino acid substitutions: D265A and N297A.
- the Fc mutant consists of the following two amino acid substitutions: D265A and N297A.
- the proline at position329 (EU numbering) (P329) of a wild-type human Fc region may be substituted with glycine or arginine or an amino acid residue large enough to destroy the proline sandwich within the Fc/Fcy receptor interface, that is formed between the P329 of the Fc and tryptophane residues W87 and W110 of FcgRIII (Sondermann et al. Nature 406, 267-273 (20 Jul. 2000)).
- At least one further amino acid substitution in the Fc variant is S228P, E233P, L234A, L235A, L235E, N297A, N297D, or P331S and still in another embodiment said at least one further amino acid substitution is L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region, all according to EU numbering (U.S. Pat. No. 8,969,526 which is incorporated by reference in its entirety).
- a polypeptide may include the Fc variant of a wild-type human IgG Fc region wherein the polypeptide has P329 of the human IgG Fc region substituted with glycine and wherein the Fc variant comprises at least two further amino acid substitutions at L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region, and wherein the residues are numbered according to the EU numbering (U.S. Pat. No. 8,969,526 which is incorporated by reference).
- the polypeptide comprising the P329G, L234A and L235A (EU numbering) substitutions may exhibit a reduced affinity to the human Fc ⁇ RIIIA and Fc ⁇ RIIA, for down-modulation of ADCC to at least 20% of the ADCC induced by the polypeptide comprising the wildtype human IgG Fc region, and/or for down-modulation of ADCP (U.S. Pat. No. 8,969,526 which is incorporated by reference).
- the polypeptide comprising an Fc variant of a wildtype human Fc polypeptide may include a triple mutation: an amino acid substitution at position Pro329, a L234A and a L235A mutation according to EU numbering (P329/LALA) (U.S. Pat. No. 8,969,526 which is incorporated by reference).
- the polypeptide comprises the following amino acid substitutions: P329G, L234A, and L235A according to EU numbering.
- An antibody variant may include an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering).
- Alterations may be made in the Fc region that result in altered (i.e., either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie et al. (2000) J. Immunol. 164:4178-4184.
- CDC Complement Dependent Cytotoxicity
- Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus are described in US2005/0014934.
- Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn.
- Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (U.S. 7,371,826) according to EU numbering. See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO 94/29351 concerning other examples of Fc region variants.
- cysteine engineered antibodies e.g., “THIOMABTM antibody”
- one or more residues of an antibody are substituted with cysteine residues.
- the substituted residues occur at accessible sites of the antibody.
- reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug intermediates, to create an immunoconjugate, as described further herein.
- any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A140 (EU numbering) of the heavy chain; L174 (EU numbering) of the heavy chain; Y373 (EU numbering) of the heavy chain; K149 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and 5400 (EU numbering) of the heavy chain Fc region.
- the antibodies described herein comprise the HC-A140C (EU numbering) cysteine substitution.
- the antibodies described herein comprise the LC-K149C (Kabat numbering) cysteine substitution.
- the antibodies described herein comprise the HC-A118C (EU numbering) cysteine substitution.
- Cysteine engineered antibodies may be generated as described, e.g., in U.S. Pat. Nos. 7,521,541; 9,000,130.
- the antibody may comprise one of the following heavy chain cysteine substitutions:
- the antibody may comprise one of the following light chain cysteine substitutions:
- a “Linker” (L) is a bifunctional or multifunctional moiety that can be used to link one or more drug moieties (D) to an antibody (Ab) to form an ADC of Formula I.
- ADC can be prepared using a Linker having reactive functionalities for covalently attaching to the drug and to the antibody.
- the cysteine thiol of a cysteine-engineered antibody (Ab) can form a bond with a reactive functional group of a linker or a drug-linker intermediate to make an ADC.
- a linker may have functionality that is capable of reacting with a free cysteine present on an antibody to form a covalent disulfide bond (See, e.g., the conjugation method at page 766 of Klussman, et al (2004), Bioconjugate Chemistry 15(4):765-773, and the Examples herein).
- Exemplary spacer components include valine-citrulline (“val-cit” or “vc”), alanine-phenylalanine (“ala-phe”), and p-aminobenzyloxycarbonyl (a “PAB”).
- val-cit or “vc”
- ala-phe alanine-phenylalanine
- PAB p-aminobenzyloxycarbonyl
- a linker may have a functionality that is capable of reacting with a free cysteine present on an antibody to form a covalent bond.
- reactive functionalities include maleimide, haloacetamides, ⁇ -haloacetyl, activated esters such as succinimide esters, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates.
- a linker may have a functionality that is capable of reacting with an electrophilic group present on an antibody.
- electrophilic groups include, but are not limited to, aldehyde and ketone carbonyl groups.
- a heteroatom of the reactive functionality of the linker can react with an electrophilic group on an antibody and form a covalent bond to an antibody unit.
- Nonlimiting examples of such reactive functionalities include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.
- a linker may comprise one or more linker components.
- exemplary linker components include 6-maleimidocaproyl (“MC”), maleimidopropanoyl (“MP”), valine-citrulline (“valcit” or “vc”), alanine-phenylalanine (“ala-phe”), p-aminobenzyloxycarbonyl (a “PAB”), N-Succinimidyl 4-(2-pyridylthio) pentanoate (“SPP”), and 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (“MCC”).
- MC 6-maleimidocaproyl
- MP maleimidopropanoyl
- valcit valine-citrulline
- alanine-phenylalanine ala-phe
- PAB p-aminobenzyloxycarbonyl
- SPP N-Succinimidyl 4-(2-pyridylthio) pent
- a linker may be a “cleavable linker,” facilitating release of a drug.
- Nonlimiting exemplary cleavable linkers include acid-labile linkers (e.g., comprising hydrazone), protease-sensitive (e.g., peptidase-sensitive) linkers, photolabile linkers, or disulfide-containing linkers (Chari et al., Cancer Research 52:127-131 (1992); U.S. Pat. No. 5,208,020).
- a linker may comprise one or more spacer units between the disulfide group and the drug moiety.
- An example includes a linker having the following formula
- A is a “stretcher unit”, and a is an integer from 0 to 1; W is an “amino acid unit”, and w is an integer from 0 to 12; Y is a “spacer unit”, and y is 0, 1, or 2; and Ab, D, and p are defined as above for Formula I.
- Exemplary embodiments of such linkers are described in U.S. Pat. No. 7,498,298, which is expressly incorporated herein by reference.
- a linker component may include a “stretcher unit” that links an antibody to another linker component or to a drug moiety.
- stretcher units are shown below (wherein the wavy line indicates sites of covalent attachment to an antibody, drug, or additional linker components):
- the linker may be a peptidomimetic linker such as those described in WO2015/095227, WO2015/095124 or WO2015/095223, which documents are hereby incorporated by reference.
- the site specific ADC compounds of the invention comprise an antibody conjugated to one or more drug moieties, including the following:
- an ADC comprises an antibody conjugated to one or more maytansinoid molecules.
- Maytansinoids are derivatives of maytansine, and are mitotic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub Maytenus serrata (U.S. Pat. No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Pat. No. 4,151,042). Synthetic maytansinoids are disclosed, for example, in U.S. Pat. No. 4,137,230; U.S. Pat. No. 4,248,870; U.S. Pat. No.
- Maytansinoid drug moieties are attractive drug moieties in antibody-drug conjugates because they are: (i) relatively accessible to prepare by fermentation or chemical modification or derivatization of fermentation products, (ii) amenable to derivatization with functional groups suitable for conjugation through non-disulfide linkers to antibodies, (iii) stable in plasma, and (iv) effective against a variety of tumor cell lines.
- Certain maytansinoids suitable for use as maytansinoid drug moieties are known in the art and can be isolated from natural sources according to known methods or produced using genetic engineering techniques (see, e.g., Yu et al (2002) Proc. Natl. Acad. Sci. U.S.A. 99:7968-7973). Maytansinoids may also be prepared synthetically according to known methods.
- Exemplary maytansinoid drug moieties include, but are not limited to, those having a modified aromatic ring, such as: C-19-dechloro (U.S. Pat. No. 4,256,746) (prepared, for example, by lithium aluminum hydride reduction of ansamytocin P2); C-20-hydroxy (or C-20-demethyl)+/ ⁇ C-19-dechloro (U.S. Pat. Nos. 4,361,650 and 4,307,016) (prepared, for example, by demethylation using Streptomyces or Actinomyces or dechlorination using LAH); and C-20-demethoxy, C-20-acyloxy (—OCOR), +/ ⁇ dechloro (U.S. Pat. No. 4,294,757) (prepared, for example, by acylation using acyl chlorides), and those having modifications at other positions of the aromatic ring.
- C-19-dechloro U.S. Pat. No. 4,256,746
- Exemplary maytansinoid drug moieties also include those having modifications such as: C-9-SH (U.S. Pat. No. 4,424,219) (prepared, for example, by the reaction of maytansinol with H 2 S or P 2 S 5 ); C-14-alkoxymethyl(demethoxy/CH 2 OR)(U.S. Pat. No. 4,331,598); C-14-hydroxymethyl or acyloxymethyl (CH 2 OH or CH 2 OAc) (U.S. Pat. No. 4,450,254) (prepared, for example, from Nocardia); C-15-hydroxy/acyloxy (U.S. Pat. No.
- 4,364,866 (prepared, for example, by the conversion of maytansinol by Streptomyces ); C-15-methoxy (U.S. Pat. No. 4,313,946 and U.S. Pat. No. 4,315,929) (for example, isolated from Trewia nudlflora); C-18-N-demethyl (U.S. Pat. No. 4,362,663 and U.S. Pat. No. 4,322,348) (prepared, for example, by the demethylation of maytansinol by Streptomyces ); and 4,5-deoxy (U.S. Pat. No. 4,371,533) (prepared, for example, by the titanium trichloride/LAH reduction of maytansinol).
- an ester linkage may be formed by reaction with a hydroxyl group using conventional coupling techniques. The reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group.
- the linkage is formed at the C-3 position of maytansinol or a maytansinol analogue.
- Maytansinoid drug moieties include those having the structure:
- Each R may independently be H or a C 1 -C 6 alkyl.
- the alkylene chain attaching the amide group to the sulfur atom may be methanyl, ethanyl, or propyl, i.e., m is 1, 2, or 3 (U.S. Pat. No. 633,410; U.S. Pat. No. 5,208,020; Chari et al (1992) Cancer Res. 52:127-131; Liu et al (1996) Proc. Natl. Acad. Sci USA 93:8618-8623).
- the maytansinoid drug moiety has the following stereochemistry:
- Exemplary embodiments of maytansinoid drug moieties include, but are not limited to, DM1; DM3; and DM4, having the structures:
- Immunoconjugates containing maytansinoids, methods of making the same, and their therapeutic use are disclosed, for example, in U.S. Pat. No. 5,208,020 and U.S. Pat. No. 5,416,064; US 2005/0276812 A1; and European Patent EP 0 425 235 B1, the disclosures of which are hereby expressly incorporated by reference. See also Liu et al. Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996); and Chari et al. Cancer Research 52:127-131 (1992).
- Antibody-maytansinoid conjugates may be prepared by chemically linking an antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. See, e.g., U.S. Pat. No. 5,208,020 (the disclosure of which is hereby expressly incorporated by reference).
- ADCs with an average of 3-4 maytansinoid molecules conjugated per antibody molecule have shown efficacy in enhancing cytotoxicity of target cells without negatively affecting the function or solubility of the antibody. In some instances, even one molecule of toxin/antibody is expected to enhance cytotoxicity over the use of naked antibody.
- Exemplary linking groups for making antibody-maytansinoid conjugates include, for example, those described herein and those disclosed in U.S. Pat. No. 5,208,020; EP Patent 0425235; Chari et al. Cancer Research 52:127-131 (1992); US 2005/0276812; and US 2005/016993, the disclosures of which are hereby expressly incorporated by reference.
- Drug moieties may include dolastatins, auristatins, and analogs and derivatives thereof (U.S. Pat. No. 5,635,483; U.S. Pat. No. 5,780,588; U.S. Pat. No. 5,767,237; U.S. Pat. No. 6,124,431).
- Auristatins are derivatives of the marine mollusk compound dolastatin-10. While not intending to be bound by theory, dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cellular division (Woyke et al (2001) Antimicrob. Agents and Chemother.
- the dolastatin/auristatin drug moiety may be attached to the antibody through the N (amino) terminus or the C (carboxyl) terminus of the peptidic drug moiety (WO 02/088172; Doronina et al (2003) Nature Biotechnology 21(7):778-784; Francisco et al (2003) Blood 102(4):1458-1465).
- Exemplary auristatin embodiments include the N-terminus linked monomethylauristatin drug moieties disclosed in U.S. Pat. No. 7,498,298 and U.S. Pat. No. 7,659,241, the disclosures of which are expressly incorporated by reference in their entirety:
- An exemplary auristatin embodiment of formula D E is MMAE, wherein the wavy line indicates the covalent attachment to a linker (L) of an antibody-drug conjugate:
- An exemplary auristatin embodiment of formula D F is MMAF, wherein the wavy line indicates the covalent attachment to a linker (L) of an antibody-drug conjugate:
- exemplary embodiments include monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007/008848) and monomethylvaline compounds having phenylalanine sidechain modifications at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007/008603).
- peptide-based drug moieties can be prepared by forming a peptide bond between two or more amino acids and/or peptide fragments.
- Such peptide bonds can be prepared, for example, according to a liquid phase synthesis method (see, e.g., E. Schröder and K. Lübke, “The Peptides”, volume 1, pp 76-136, 1965, Academic Press).
- Auristatin/dolastatin drug moieties may be prepared according to the methods of: U.S. Pat. No. 7,498,298; U.S. Pat. No. 5,635,483; U.S. Pat. No. 5,780,588; Pettit et al (1989) J. Am. Chem. Soc.
- Auristatin/dolastatin drug moieties of formulas D E such as MMAE, and D F, such as MMAF, and drug-linker intermediates and derivatives thereof, such as MC-MMAF, MC-MMAE, MC-vc-PAB-MMAF, and MC-vc-PAB-MMAE, may be prepared using methods described in U.S. Pat. No. 7,498,298; Doronina et al. (2006) Bioconjugate Chem. 17:114-124; and Doronina et al. (2003) Nat. Biotech. 21:778-784and then conjugated to an antibody of interest.
- the calicheamicin family of antibiotics, and analogues thereof, are capable of producing double-stranded DNA breaks at sub-picomolar concentrations (Hinman et al., (1993) Cancer Research 53:3336-3342; Lode et al., (1998) Cancer Research 58:2925-2928).
- Calicheamicin has intracellular sites of action but, in certain instances, does not readily cross the plasma membrane. Therefore, cellular uptake of these agents through antibody-mediated internalization may, in some embodiments, greatly enhances their cytotoxic effects.
- Nonlimiting exemplary methods of preparing antibody-drug conjugates with a calicheamicin drug moiety are described, for example, in U.S. Pat. No. 5,712,374; U.S. Pat. No. 5,714,586; U.S. Pat. No. 5,739,116; U.S. Pat. No. 5,767,285; and WO 2017/068511.
- the drug moiety conjugated to the antibody is a calicheamicin compound having the formula:
- An ADC may comprise a pyrrolobenzodiazepine (PBD) drug moiety.
- PDB dimers may recognize and bind to specific DNA sequences.
- the natural product anthramycin, a PBD was first reported in 1965 (Leimgruber, et al., (1965) J. Am. Chem. Soc., 87:5793-5795; Leimgruber, et al., (1965) J. Am. Chem. Soc., 87:5791-5793). Since then, a number of PBDs, both naturally-occurring and analogues, have been reported (Thurston, et al., (1994) Chem. Rev.
- dimers of the tricyclic PBD scaffold U.S. Pat. No. 6,884,799; U.S. Pat. No. 7,049,311; U.S. Pat. No. 7,067,511; U.S. Pat. No. 7,265,105; U.S. Pat. No. 7,511,032; U.S. Pat. No. 7,528,126; U.S. Pat. No. 7,557,099).
- the dimer structure imparts the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In Antibiotics III. Springer-Verlag, New York, pp.
- PBD compounds can be employed as prodrugs by protecting them at the N10 position with a nitrogen protecting group which is removable in vivo (WO 00/12507; WO 2005/023814).
- PBD dimers have been conjugated to antibodies and the resulting ADC shown to have anti-cancer properties (US 2010/0203007).
- Nonlimiting exemplary linkage sites on the PBD dimer include the five-membered pyrrolo ring, the tether between the PBD units, and the N10-C11 imine group (WO 2009/016516; US 2009/304710; US 2010/047257; US 2009/036431; US 2011/0256157; WO 2011/130598).
- a linker may be attached at one of various sites of the PBD dimer drug moiety, including the N10 imine of the B ring, the C-2 endo/exo position of the C ring, or the tether unit linking the A rings (see structures C(I) and C(II) below).
- an exemplary PBD dimer component of an ADC has the structure of Formula A-1:
- an exemplary PBD dimer component of an ADC has the structure of Formula A-2:
- an exemplary PBD dimer component of an ADC has the structure of Formula A-3:
- R E and R E′′ are each independently selected from H or R D , wherein R D is defined as above;
- n 0 or 1.
- n is 0. In some embodiments, n is 1. In some embodiments, R E and/or R E′′ is H. In some embodiments, R E and R E′′ are H. In some embodiments, R E and/or R E′′ is R D , wherein R D is optionally substituted C 1-12 alkyl. In some embodiments, R E and/or R E′′ is R D , wherein R D is methyl.
- an exemplary PBD dimer component of an ADC has the structure of Formula A-4:
- Ar 1 and Ar 2 are each independently optionally substituted C 5-20 aryl; wherein Ar 1 and Ar2 may be the same or different; and
- n 0 or 1.
- An exemplary PBD dimer component of an ADC has the structure of Formula A-5:
- Ar 1 and Ar 2 are each independently optionally substituted C 5-20 aryl; wherein Ar 1 and Ar2 may be the same or different; and
- n 0 or 1.
- Ar 1 and Ar2 may each, independently, be selected from optionally substituted phenyl, furanyl, thiophenyl and pyridyl.
- Ar 1 and Ar 2 are each independently optionally substituted phenyl.
- Ar 1 and Ar 2 are each independently optionally substituted thien-2-yl or thien-3-yl.
- Ar 1 and Ar 2 are each independently optionally substituted quinolinyl or isoquinolinyl. The quinolinyl or isoquinolinyl group may be bound to the PBD core through any available ring position.
- the quinolinyl may be quinolin-2-yl, quinolin-3-yl, quinolin-4yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl and quinolin-8-yl.
- the quinolinyl is selected from quinolin-3-yl and quinolin-6-yl.
- the isoquinolinyl may be isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl.
- the isoquinolinyl is selected from isoquinolin-3-yl and isoquinolin-6-yl.
- An exemplary PBD dimer component of an ADC has the structure of Formula A-6:
- the wavy line indicates the covalent attachment site to the linker
- R V1 and R V2 are independently selected from H, methyl, ethyl and phenyl (which phenyl may be optionally substituted with fluoro, particularly in the 4 position) and C 5-6 heterocyclyl; wherein R V1 and R V2 may be the same or different; and
- n 0 or 1.
- R V1 and R V2 may, independently, be selected from H, phenyl, and 4-fluorophenyl.
- Nonlimiting exemplary PBD dimer components of ADC include tether-linked Formulas C(I) and C(II):
- Formulas C(I) and C(II) are shown in their N10-C11 imine form.
- Exemplary PBD drug moieties also include the carbinolamine and protected carbinolamine forms as well, as shown in the table below:
- Z and Z′ are independently selected from OR and NR 2, where R is a primary, secondary or tertiary alkyl chain containing 1 to 5 carbon atoms;
- R 1 , R′ 1 , R 2 and R′ 2 are each independently selected from H, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 5-20 aryl (including substituted aryls), C 5-20 heteroaryl groups, —NH 2 , —NHMe, —OH, and —SH, where, in some embodiments, alkyl, alkenyl and alkynyl chains comprise up to 5 carbon atoms;
- R 3 and R′ 3 are independently selected from H, OR, NHR, and NR 2, where R is a primary, secondary or tertiary alkyl chain containing 1 to 5 carbon atoms;
- R4 and R′ 4 are independently selected from H, Me, and OMe;
- R 5 is selected from C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 5-20 aryl (including aryls substituted by halo, nitro, cyano, alkoxy, alkyl, heterocyclyl) and C 5-20 heteroaryl groups, where, in some embodiments, alkyl, alkenyl and alkynyl chains comprise up to 5 carbon atoms;
- R 11 is H, C 1 -C 8 alkyl, or a protecting group (such as acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), 9-fluorenylmethylenoxycarbonyl (Fmoc), or a moiety comprising a self-immolating unit such as valine-citrulline-PAB);
- a protecting group such as acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), 9-fluorenylmethylenoxycarbonyl (Fmoc), or a moiety comprising a self-immolating unit such as valine-citrulline-PAB
- R 12 is H, C 1 -C 8 alkyl, or a protecting group
- An ADC comprising a PBD dimer described herein may be made by conjugating a linker-drug intermediate including a pyridine leaving group via a sulfur atom with a cysteine thiol of an antibody to form a disulfide linkage. Further, in some embodiments, an ADC comprising a PBD dimer described herein may be made by conjugating a linker-drug intermediate including a thiopyridyl leaving group, wherein the pyridine ring is substituted with one or more nitro groups. In some embodiments, the pyridyl ring is monosubstituted with —NO 2 . In some embodiments, the —NO 2 monosubstitution is para relative to the disulfide.
- the PBD dimer is connected through the N10 position.
- non-limiting exemplary ADC comprising a PBD dimer may be made by conjugating a monomethylethyl pyridyl disulfide, N10-linked PBD linker intermediate (shown below) to an antibody:
- PBD dimers and ADCs comprising PBD dimers may be prepared according to methods known in the art. See, e.g., WO 2009/016516; US 2009/304710; US 2010/047257; US 2009/036431; US 2011/0256157; WO 2011/130598; WO 2013/055987.
- a site specific ADC of this disclosure may comprise an anthracycline.
- Anthracyclines are antibiotic compounds that exhibit cytotoxic activity. While not intending to be bound by theory, anthracyclines may operate to kill cells by a number of different mechanisms, including: 1) intercalation of the drug molecules into the DNA of the cell thereby inhibiting DNA-dependent nucleic acid synthesis; 2) production by the drug of free radicals which then react with cellular macromolecules to cause damage to the cells, and/or 3) interactions of the drug molecules with the cell membrane (see, e.g., C. Peterson et al., “Transport And Storage of Anthracycline In Experimental Systems And Human Leukemia” in Anthracycline Antibiotics In Cancer Therapy; N. R.
- anthracyclines have been used in the treatment of numerous cancers such as leukemia, breast carcinoma, lung carcinoma, ovarian adenocarcinoma and sarcomas (see e.g., P. H-Wiernik, in Anthracycline: Current Status and New Developments p 11).
- anthracyclines include doxorubicin, epirubicin, idarubicin, daunomycin, nemorubicin, and derivatives thereof. Immunoconjugates and prodrugs of daunorubicin and doxorubicin have been prepared and studied (Kratz et al (2006) Current Med. Chem. 13:477-523; Jeffrey et al (2006) Bioorganic & Med. Chem. Letters 16:358-362; Torgov et al (2005) Bioconj. Chem. 16:717-721; Nagy et al (2000) Proc. Natl. Acad. Sci. USA 97:829-834; Dubowchik et al (2002) Bioorg. & Med. Chem.
- PNU-159682 is a potent metabolite (or derivative) of nemorubicin (Quintieri, et al. (2005) Clinical Cancer Research 11(4):1608-1617).
- Nemorubicin is a semisynthetic analog of doxorubicin with a 2-methoxymorpholino group on the glycoside amino of doxorubicin and has been under clinical evaluation (Grandi et al (1990) Cancer Treat. Rev. 17:133; Ripamonti et al (1992) Brit. J.
- the nemorubicin component of a nemorubicin-containing ADC is PNU-159682.
- Anthracyclines including PNU-159682, may be conjugated to antibodies through several linkage sites and a variety of linkers (US 2011/0076287; W02009/099741; US 2010/0034837; WO 2010/009124), including the linkers described herein.
- Exemplary ADCs may be made by conjugating a pyridyl disulfide PNU amide (shown below) to an antibody:
- linker of PNU-159682, maleimide acetal-Ab is acid-labile
- linkers of PNU-159682-val-cit-PAB-Ab, PNU-159682-val-cit-PAB-spacer-Ab, and PNU-159682-val-cit-PAB-spacer(R 1 R 2 )-Ab are protease-cleavable.
- an ADC comprises 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI).
- CBI The 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indole
- amino CBI The 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indole
- DNA minor groove alkylators are potent cytotoxins (Atwell, et al (1999) J. Med. Chem., 42:3400), and have been utilized as effector units in a number of classes of prodrugs designed for cancer therapy. These have included antibody conjugates, (Jeffrey, et al. (2005) J. Med.
- a site-specific ADC may comprise a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer (WO 2015/023355).
- the dimer may be a heterodimer wherein one half of the dimer is a CBI moiety and the other half of the dimer is a PBD moiety.
- An exemplary CBI dimer comprises the formula:
- R 1 is selected from H, P(O) 3 H 2 , C(O)NR a R b , or a bond to a linker (L);
- R 2 is selected from H, P(O) 3 H 2 , C(O)NR a R b , or a bond to a linker (L);
- R a and R b are independently selected from H and C 1 -C 6 alkyl optionally substituted with one or more F, or R a and R b form a five or six membered heterocyclyl group;
- T is a tether group selected from C 3 -C 12 alkylene, Y, (C 1 -C 6 alkylene)-Y—(C 1 -C 6 alkylene), (C 1 -C 6 alkylene)-Y—(C 1 -C 6 alkylene)-Y—(C 1 -C 6 alkylene), (C 2 -C 6 alkenylene)-Y—(C 2 -C 6 alkenylene), and (C 2 -C 6 alkynylene)-Y—(C 2 -C 6 alkynylene);
- Y is independently selected from O, S, NR 1 , aryl, and heteroaryl;
- alkylene, alkenylene, aryl, and heteroaryl are independently and optionally substituted with F, OH, O(C 1 -C 6 alkyl), NH 2 , NHCH 3 , N(CH 3 ) 2 , OP(O) 3 H 2 , and C 1 -C 6 alkyl, where alkyl is optionally substituted with one or more F;
- alkylene, alkenylene, aryl, and heteroaryl are independently and optionally substituted with a bond to L;
- D′ is a drug moiety selected from:
- X 1 and X 2 are independently selected from O and NR 3 , where R 3 is selected from H and C 1 -C 6 alkyl optionally substituted with one or more F;
- R 4 is H, CO 2 R, or a bond to a linker (L), where R is C 1 -C 6 alkyl or benzyl;
- R 5 is H or C 1 -C 6 alkyl.
- the site specific ADCs may comprise one or more amatoxin molecules.
- Amatoxins are cyclic peptides composed of 8 amino acids. They can be isolated from Amanita phalloides mushrooms or prepared synthetically. Amatoxins specifically inhibit the DNA-dependent RNA polymerase II of mammalian cells, and thereby also the transcription and protein biosynthesis of the affected cells. Inhibition of transcription in a cell causes stop of growth and proliferation. See e.g., Moldenhauer et al. JNCI 104:1-13 (2012), WO2010115629, WO2012041504, WO2012119787, WO2014043403, WO2014135282, and WO2012119787, which are hereby incorporated by reference in its entirety.
- the one or more amatoxin molecules may be ⁇ -amanitin molecules.
- Drug moieties may also include geldanamycin (Mandler et al (2000) J. Nat. Cancer Inst. 92(19):1573-1581; Mandler et al (2000) Bioorganic & Med. Chem. Letters 10:1025-1028; Mandler et al (2002) Bioconjugate Chem.
- Drug moieties may also include compounds with nucleolytic activity (e.g., a ribonuclease or a DNA endonuclease).
- the resulting product is a mixture of ADC compounds with a distribution of one or more drug moieties attached to an antibody.
- Linker-drug intermediates may be prepared by coupling a drug moiety with a linker reagent, and according to the procedures of WO 2013/055987; WO 2015/023355; WO 2010/009124; WO 2015/095227, and conjugated with a protein, including cysteine engineered antibodies, described herein.
- ADCs are targeted anti-cancer therapeutics designed to reduce nonspecific toxicities and increase efficacy relative to conventional small molecule and antibody cancer chemotherapy. They employ the powerful targeting ability of monoclonal antibodies to specifically deliver highly potent, conjugated small molecule therapeutics to a cancer cell. To evaluate properties such as efficacy, stability, homology, pharmacokinetics and toxicity of these ADCs, it is useful to accurately characterize and quantify the antibody component and drug moiety from solution, plasma, urine, and other biological samples, via sample analytical analyses.
- FIG. 2 shows a cartoon of the work flow in an ADC sample assay of this disclosure, including the optional affinity capture of an ADC from a sample, site specific enzymatic digestion, which may include drug cleavage and release from the ADC, and subsequent analysis of the drug and peptide fragments by chromatography and/or spectrometry methods.
- the site specific ADC construct is digested with one or more specific enzymes to form a digested ADC composition containing at least one peptide fragment that is not linked to the drug moiety, and at least one peptide fragment that is linked to the drug moiety.
- Either one or both of the drug and digested antibody component(s)/fragment are then analyzed by chromatography/spectrometry to determine characteristics of the ADC, which may include, but are not limited to, the protein concentration of the ADC composition, the total antibody concentration of the ADC, the drug concentration and/or the average DAR of the ADC, ADC metabolite or catabolite structures, and the extinction coefficient of the ADC.
- the protein component of the ADC sample may be digested with a proteolytic enzyme such as an IdeS protease, an IdeZ protease, an IgdE protease, a SpeB protease, a gingipain protease, an endoglycosidase, and combinations of these enzymes.
- a proteolytic enzyme such as an IdeS protease, an IdeZ protease, an IgdE protease, a SpeB protease, a gingipain protease, an endoglycosidase, and combinations of these enzymes.
- IdeS is an extracellular cysteine proteinase produced by S. pyogenes and available commercially from Promega (Madison, Wisc.) and Genovis AB (Cambridge, Mass.).
- This enzyme designated IdeS for Immunoglobulin G-degrading enzyme of S. pyogenes, cleaves human IgG below the hinge region with a high degree of specificity yielding a homogenous pool of F(ab′)2 and Fc fragments.
- other human proteins including immunoglobulins M, A, D and E, are not digested by IdeS.
- the enzyme efficiently cleaves IgG antibodies bound to streptococcal surface structures, thereby inhibiting the killing of S.
- proteolytic cleavage site of the IdeS enzyme is shown in the following table:
- IgG Species and Subclasses IdeS cleavage site SEQ ID No. Human IgG1 . . . CPAPELLG/GPSVF. . . 1 Human IgG2 . . . CPAPPVA/GPSVF. . . 2 Human IgG3 . . . CPAPPVA/GPSVF. . . 2 Human IgG4 . . . CPAPPVA/GPSVF. . . 2 Mouse IgG1 Does not cut Mouse IgG2a . . . CPAPPVA/GPSVF. . . 2 Mouse IgG2b Does not cut Mouse IgG3 . . . CPAPPVA/GPSVF. . .
- IdeZ Protease (IgG-specific) is an antibody-specific protease cloned from Streptococcus equi subspecies zooepidemicus that recognizes all human, sheep, monkey, and rabbit IgG subclasses, specifically cleaving at a single recognition site below the hinge region, yielding a homogenous pool of F(ab′)2 and Fc fragments, and is commercially available from New England Biolabs (Ipswich, Mass.), Promega (Madison, Wis.), and Genovis AB (Cambridge, Mass.). IdeZ Protease has significantly improved activity against mouse IgG2a and IgG3 subclasses compared to the IdeS Protease.
- IgdE is a protease of Streptococcus suis that exclusively targets porcine IgG.
- This enzyme designated IgdE for immunoglobulin G-degrading enzyme of S. suis, is a cysteine protease distinct from streptococcal immunoglobulin degrading proteases of the IdeS family and cleaves the hinge region of porcine IgG with a high degree of specificity (Spoerry, et al., J Biol Chem. (2016) 291(15):7915-25).
- SpeB is a cysteine protease isolated from Streptococcus pyogenes, which degrades IgA, IgM, IgE, and IgD, and cleaves IgG antibodies in the hinge region after reduction, i.e., cleaves IgG molecules in a reduced state, e.g., in the presence of dithiothreitol (DTT), ⁇ -mercaptoethanol, or L-cysteine (Persson, et al., Infect. Immun. (2013) 81(6):2236-41).
- DTT dithiothreitol
- ⁇ -mercaptoethanol e.g., ⁇ -mercaptoethanol
- L-cysteine Persson, et al., Infect. Immun. (2013) 81(6):2236-41.
- Gingipain Kgp (also referred to as Lys-gingipain) is a cysteine protease secreted by Porphyromonas gingivalis, which cleaves human IgG1 in the upper hinge region (between K223 and T224) fragments under mild reducing conditions, producing a homogenous pool of Fab and Fc.
- a recombinant form of Gingipain Kgp is commercially available from Genovis AB (Cambridge, Mass.).
- Endoglycosidases represent a family of enzymes expressed by Streptococcus pyogenes capable of releasing the terminal sialic acid residues from glycoproteins such as immunoglobulins, and Asp279 of IgG in particular.
- EndoS is a specific endoglycosidase used to deglycosylate antibodies.
- Additional endoglycosidases that may be useful in the methods of this disclosure include one or more of Endo S2, EndoH, EndoA, EndoM, EndoF, EndoF1, EndoF2, and EndoF3.
- Endoglycosidases may be used in the assays of this disclosure in combination with one or more of the proteases described above in preparation of the digested site specific ADC for chromatographic/spectrometric analysis.
- the proteolytic enzyme(s) used to digest the site specific ADC construct may be chosen to produce a unique peptide fragment for detection and quantitation.
- One or more of the peptide fragments unique to the antibody of the ADC is detected and quantified, thereby eliminating background or non-specific proteins or other contaminants that may be present in the analysis sample applied to the chromatography or spectrometry, that do not form part of the ADC.
- the ADC sample is not digested with trypsin, papain, pepsin, endoproteinase LysC, endoproteinase ArgC, staph aureus V8, chymotrypsin, Asp-N, Asn-C, PNGaseF, endoproteinase GluC, LysN, or any combinations of these enzymes.
- the ADC sample in the digestion or analysis procedures, contains no detectable amounts of trypsin, papain, pepsin, endoproteinase LysC, endoproteinase ArgC, staph aureus V8, chymotrypsin, Asp-N, Asn-C, PNGaseF, endoproteinase GluC, or LysN.
- the drug moiety of the ADC may be cleaved from the antibody/peptide component of the ADC and may therefore be detected and quantified as an unconjugated drug component in the LC-MS/MS analysis.
- the drug moiety component of the ADC may remain linked to the antibody/peptide component of the ADC following reduction and denaturation of the ADC, and may therefore be detected and quantified as a peptide-bound drug moiety in the analysis.
- the sample containing the ADC for analysis/quantification may be subjected to digestion (and optionally reduction and/or denaturation) without any preliminary sample clean up or enrichment (i.e., “direct digestion” of the sample).
- the sample containing the ADC may be enriched or concentrated for further analysis, prior to digestion.
- Such concentration of low-abundance peptides or drugs may include enrichment techniques such as size exclusion chromatography, dialysis, selective precipitation, differential centrifugation, filtration, gel electrophoresis, liquid chromatography, reversed-phase chromatography, immunoprecipitation, SpinTrap columns including protein A and protein G, NHS and streptavidin iron or phosphorus or immobilized antibodies or lectin, paramagnetic beads, immuno-depletion, fractionation, solid phase extraction, phosphopeptide enrichment, polyacrylamide gel electrophoresis, desalting, and the like.
- enrichment techniques such as size exclusion chromatography, dialysis, selective precipitation, differential centrifugation, filtration, gel electrophoresis, liquid chromatography, reversed-phase chromatography, immunoprecipitation, SpinTrap columns including protein A and protein G, NHS and streptavidin iron or phosphorus or immobilized antibodies or lectin, paramagnetic beads, immuno-depletion, fractionation, solid phase
- the ADC may be reduced by contact with a composition that includes at least one reductant, for example dithiothreitol (DTT), 2-mercaptoethanol, or tris(2-carboxyethyl)phosphine (TCEP).
- the ADC may also be denatured by contact with a composition that includes at least one denaturant, for example formamide, dimethylformamide, acetonitrile, SDS, urea, guanidine, sodium 3-((1-(furan-2-yl)undecyloxy)carbonylamino)propane-1-sulfonate (ProteaseMaxTM), and/or an acid labile surfactant(s) such as those containing a dioxolane or dioxane functional group, such as RapiGestTM-SF-surfactant (as described in U.S.
- the ADC may be simultaneously reduced and denatured by contact with a composition that includes at least one reductant and at least one denaturant.
- a composition that includes at least one reductant and at least one denaturant.
- Such compositions may include additional solvents, buffers and/or pH modifying agents, such as acetonitrile, methanol, ethanol, HCl, ammonium bicarbonate, ammonium acetate, and/or formic acid, dephosphorylating agents including phosphatases such as calf intestinal alkaline phosphatase, bovine intestinal alkaline phosphatase, or lambda protein phosphatase.
- the ADC presented for analysis may also be present in a solution or suspension, such as a pharmaceutical composition formulated for administration to an animal or human, or in cell culture or supernatant that may be present in a production step of the ADC, or in a biological sample obtained from an animal or a human.
- the ADC may be present in a matrix selected from a buffer, whole blood, serum, plasma, cerebrospinal fluid, saliva, urine, lymph, bile, feces, sweat, vitreous, tears, and tissue.
- Biological samples that are frequently presented for analysis of various safety, efficacy and pharmacokinetic/biodistribution parameters of ADCs include human, cynomolgus monkey, rat, and mouse plasma and tissue samples, as well as biological samples from other non-human species.
- the ADC When presented as part of such biological samples, the ADC may be contacted with an affinity capture media.
- Affinity capture is a widely used method to enrich/isolate intact proteins, to identify binding partners and protein complexes, or to investigate post-translational modifications.
- the protein or protein complexes may be separated by non-specific means (e.g., gel electrophoresis, Protein A or G media, type 1 antineuronal nuclear autoantibody (ANNA-1, also known as “anti-Hu”), or specific means (e.g., extracellular domain (ECD) antibodies, or anti-idotypic antibodies).
- the ADC may then be eluted from the affinity capture media as a means of sample cleanup prior to digestion (optionally including reduction and/or denaturation), and subsequent chromatography/spectrometry analysis of the digest.
- the ADC sample is analyzed with an affinity capture by bead- or resin-supported Protein A/G, followed by on-bead digestion (which may include proteolysis, deglycosylation, dephosphorylation, reduction, and/or denaturation) prior to elution of an enriched, digested antibody sample from the affinity capture media, and subsequent chromatography/spectrometry analysis.
- on-bead digestion which may include proteolysis, deglycosylation, dephosphorylation, reduction, and/or denaturation
- IAM Immunoaffinity membrane
- the analysis sample(s) (or at least a portion thereof) comprising one or both of the drug (or peptide-linker-drug) and the digested antibody components of the site specific ADC is then applied to a detection methodology that may include high performance liquid chromatography (HPLC), reverse-phase liquid chromatography (RP-LC), mass spectrometry (MS) or tandem mass spectrometry (MS/MS), RP-LC/MS and LC-MS/MS, to detect and quantify both the drug and antibody component of the ADC.
- HPLC high performance liquid chromatography
- RP-LC reverse-phase liquid chromatography
- MS mass spectrometry
- MS/MS tandem mass spectrometry
- RP-LC/MS tandem mass spectrometry
- Mass spectrometry may be used to establish the mass to charge ratio of at least one peptide fragment of the digested antibody, and/or the mass to charge ratio of the drug (or peptide-linker-drug) moiety of the ADC.
- the molar extinction coefficient (or mass attenuation coefficient) is equal to the molar attenuation coefficient times the molar mass.
- the molar extinction coefficient of a protein at 280 nm depends almost exclusively on the number of aromatic residues, particularly tryptophan, and can be predicted from the sequence of amino acids. Thus, if the molar extinction coefficient is known, it can be used to determine the concentration of the protein in solution.
- Human lithium heparin plasma was purchased from BioreclamationIVT (New York, U.S.A.). Streptavidin-coated Dynabeads M-280 were purchased from Invitrogen (CA, U.S.A.). IdeS, i.e. FabRICATOR, was purchased from Genovis, Inc. (Cambridge, Mass.). Other reagents included HBS-EP buffer containing 0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Polysorbate 20 (GE Healthcare; Little Chalfont, U.K.) and the peptide N-glycosidase F (PNGase F; ProZyme; CA, U.S.A.).
- ECD ECD capture reagents
- Sulfo-NHS-LC-biotin Pierce/Thermo Fisher Scientific, Rockford, Ill., U.S.A.
- Biotinylated ECD concentration was determined spectrophotometrically by measuring the absorbance at 280 nm using GeneQuant 1300 (GE Healthcare).
- the affinity capture LC-MS assay was conducted for site-specific ADCs, including TDCs with conjugation sites in the Fab region (Su' D. et al (2016) Anal. Chem., 88(23):11340-11346; Xu, K.; et al. (2013) Bioanalysis, 5, 1057-1071; U.S. Pat. No. 8,541,178; Xu, K.; et al Anal. Biochem. (2011) 412:56-66).
- IdeS protease FIG. 1 ) removed the glycan-containing Fc region at specific sites, thereby reducing the size of analytes and heterogeneity of ADC catabolites.
- FIG. 2 provides a cartoon illustration of the 2nd-generation LC-MS assay tested in this Example
- FIG. 3 shows a cartoon illustration comparing embodiments of the 1 st generation and 2 nd generation assays that were tested and compared in this Example.
- ECD and anti-human (Fab region) antibody were biotinylated with 10 molar equivalent of Sulfo-NHS-LC-biotin (Pierce/Thermo Fisher Scientific, Rockford, Ill., USA) to ECD or anti-human (Fab region) antibody for 60 min at room temperature in 10 mM sodium phosphate/150 mM NaCl, pH 7.8. Excess unbound biotin was removed using ZEBATM spin desalting column (Pierce/Thermo Fisher Scientific), per manufacturer's protocol. Biotinylated ECD or anti-human (Fab region) antibody concentration was determined spectrophotometrically by measuring absorbance at 280 nm using GENEQUANTTM 1300 (GE Healthcare).
- streptavidin paramagnetic beads Streptavidin-coated Dynabeads M-280; Invitrogen (CA, USA
- 100 ⁇ L of streptavidin paramagnetic beads were added to a 96-deep-well plate containing an excess amount of biotinylated specific capture reagents, e.g., ECD, in HBS-EP buffer (300 ⁇ L; 0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% P20 (GE Healthcare; Little Chalfont, UK)) and incubated with agitation at room temperature (RT) for 1 h.
- ECD biotinylated specific capture reagents
- TDC-containing plasma samples were then added (a maximum amount of 2 ⁇ g or 250 ⁇ L, whichever is less) to the ECD-immobilized beads to a total volume of 300-500 ⁇ L, and incubated with agitation at RT for 1.5 h.
- biotinylated anti-human IgG F(ab′)2 antibody is useful for capture for all different humanized therapeutic antibody ADC and is appropriate in a study with different therapeutic arms, or where no specific ECD is available.
- Results from the 2nd-generation LC-MS assay show that generic anti-human IgG F(ab′)2 is similar to specific ECD capture of ADC analytes.
- Affinity capture was carried out on a KingFisher 96 magnetic particle processor (Thermo Electron) using 2-mL square-top 96-deep-well plates (Analytical Sales and Service, Pompton Plains, N.J., USA). Elute was transferred to a VWR Dynablock 96 well 0.5 ml plate (VWR Scientific Products).
- Capillary RPLC-MS was carried out on a Waters nanoACQUITY UPLC (Cambridge, Mass., USA) coupled with AB Sciex 5600 triple time-of-flight (TOF) mass spectrometer (Redwood City, USA).
- Affinity captured TDCs were digested with IdeS protease (FABRICATORTM, Genovis AB) (40 units) in HBS-EP buffer (300 ⁇ L) at 37° C. for 1 h, in contrast to PNGase F (PROZYMETM; CA) digestion for overnight as described in the 1st-generation method. All agitation was carried out carefully, ensuring that beads were well suspended in solution throughout the digestion procedure. Newly-generated F(ab′)2 fragments were washed sequentially with HBS-EP buffer, water and 10% ACN on beads, and then eluted by incubation in 50 ⁇ L of 30% acetonitrile with 1% formic acid at RT for 10 min.
- the subsequent F(ab′)2 elution was spun in a Bruker centrifuge at 4000 rpm for 10 min at RT and then transferred to a 96-well plate to remove residual beads with a magnet. Final elution was spun at 4000 rpm for 10 min at RT prior to LC-MS to avoid injection of any residual beads. An aliquot of 5 ⁇ L of F(ab′)2 elution was submitted for LC-MS analysis.
- Capillary LC-MS was performed on a TripleTOF 5600 mass spectrometer coupled with a Waters NanoAcquity. On-line desalting and pre-concentration were conducted on a PS-DVB monolithic column (500- ⁇ m i.d. ⁇ 5 cm, Thermo Fisher Scientific, Waltham, Mass.) at 65° C. using a gradient condition at a flow rate of 15 ⁇ L/min with mobile phases A, 0.1% formic acid (FA) and B, acetonitrile (ACN) with 0.1% FA.
- A formic acid
- ACN acetonitrile
- LC flow was diverted to waste for the first 6 min.
- TripleTOF 5600 was operated with a DuoSpray Ion Source with the following key settings: ion source temperature, 425.0° C.; Ion source gas (GS)1, 40; GS2, 35; Curtain gas, 30; IonSpray Voltage Floating, 5000V; declustering potential, 250; collision energy, 20. Mass spectra were acquired in the intact protein mode, using ANALYSTTM TF 1.6.
- DAR profiling by direct LC-MS of TDC mixtures at known ratios allowed determination of whether all individual DARs have similar LC-MS response. For example, if the relative DAR ratios by direct LC-MS are consistent with the theoretical values, there is no significant bias against any individual DAR species in LC recovery and ionization efficiency. Consistency in DAR profiling by affinity capture LC-MS and direct LC-MS would suggest unbiased recovery of individual DAR species during the affinity enrichment process.
- FIGS. 4-6 shows a comparison among direct LC-MS ( FIG. 4 ), 1st-generation ( FIGS. 5 ) and 2nd-generation ( FIG. 6 ) affinity capture LC-MS by injecting the same amount of starting TDC standard mixture.
- the example TDC contains a pyrrolobenzodiazepine dimer (PBD) as the cytotoxic drug payload.
- PBD pyrrolobenzodiazepine dimer
- Similar retention time and charge envelopes suggested no significant differences in ionization efficiency of different TDC DAR species allowing for semi-quantification using relative ratios of individual DAR species based on their peak areas in the deconvoluted mass spectra.
- ADC catabolites contained glycations and/or other modifications.
- the PNGaseF digestion, 1st-generation, affinity capture LC-MS assay method uses a TDC (THIOMAB® antibody drug conjugate) standard mixture that included a cysteine-engineered, anti-MUC16 antibody conjugated to the cytotoxic drug monomethyl auristatin E (MMAE) via a maleimido-caproyl-valine-citrulline-para-amino-benzyloxycarbonyl (MC-vc-PAB) linker.
- TDC TDC
- MMAE cytotoxic drug monomethyl auristatin E
- MC-vc-PAB maleimido-caproyl-valine-citrulline-para-amino-benzyloxycarbonyl
- the difference of measured DAR0:DAR2 from the theoretical value was pronounced by the 1st-generation and/or IdeS protease-overnight digestion affinity capture LC-MS, indicating that on-bead digestion for long hours (e.g., overnight) caused potential biased recovery of individual DARs during the affinity enrichment step.
- Reduced and optimized incubation time for ECD immobilization, ADC and ECD binding, and on-bead digestion steps in the 2nd-generation affinity capture LC-MS minimized potential biased capture of different DARs and therefore provided more accurate information on DAR profiling.
- the advantages of the 2nd-generation affinity capture LC-MS include:
- MS intensity by the 2nd-generation LC-MS (230 cps at maximum) was higher than by the 1st-generation analysis (48 cps at maximum).
- the 2nd-generation affinity capture LC-MS allows detection of TDCs as low as approximately 20 ng (0.2 ⁇ g/mL ⁇ 100 ⁇ L).
- Adjacent MS peaks are better resolved by the 2nd-generation assay.
- Fc removal by the IdeS protease is completed within about 1 h, greatly improving the assay efficiency (1 day for the 2nd-generation LC-MS vs. 2 days for the 1st-generation LC-MS).
- Affinity capture LC-MS was specifically designed to identify ADC catabolites, characterize DAR profiles, and thereby understand the fate and PK behaviors of circulating ADCs. It is therefore important to retain ADC integrity throughout the sample preparation process, in order to accurately reflect in vivo biotransformations.
- ADCs containing labile cytoxic drugs were observed to undergo unintended changes, such as ex vivo payload metabolism after incubation for long hours ( FIG. 9 ).
- FIG. 9 Analysis of a labile TDC, TDC-L2 in rat plasma in vivo by affinity capture LC-MS intact antibody assay (left) and F(ab′)2 assay ( FIG.
- Human plasma (100 ⁇ L) containing spiked TDC standard mixture was used for the affinity capture and 5 ⁇ L eluent was injected for LC-MS analysis.
- Human plasma 100 ⁇ L
- TDC standard mixture was used for the affinity capture and 5 ⁇ L elute was injected for LC-MS analysis.
- FIGS. 7 and 8 show linker-drug deconjugation (-LD) by cleavage of the thiol-maleimide bond.
- -LD linker-drug deconjugation
- Multiple TDC catabolites were generated in mouse plasma in vivo, due to loss of 42 Da from the drug molecule.
- Their MS peaks were not resolved by PNGaseF digestion, 1st-generation affinity capture LC-MS ( FIG. 7 ), but were near baseline-resolved by the IdeS digestion, 2nd-generation affinity capture LC-MS ( FIG. 8 ), which enabled confident catabolite identification and more accurate DAR calculation.
- FIGS. 7 and 8 show characterization of complicated TDC catabolites in mouse plasma in vivo by affinity capture LC-MS intact antibody assay ( FIG. 7 ) vs. affinity capture LC-MS F(ab′)2 assay ( FIG. 8 ). Partial drug loss by linker-drug deconjugation (-PD) significantly affected the potency of TDC-L1, leading to the reduction of DAR accordingly
- the 2nd-generation affinity capture method employed in this comparative example utilized the IdeS protease for deglycosylation by removing the Fc fragments where the majority of glycans are located.
- the resulting F(ab′)2 fragments (about 100 kDa) which retain the linker-drugs, are analyzed by LC-MS, instead of the traditional intact ADCs (about 150 kDa).
- DAR immobilization, ADC and ECD binding, and on- profile, drug modification or decomposition, and bead digestion steps therefore kept the ADC integrity
- the affinity capture LC-MS F(ab′)2 assay was extended to analysis of conventional ADCs, where drug is bound via inter-chain disulfides. Without IdeS protease digestion, after overnight deglycosylation by PNGase F, LC separation was needed to elute the Light Chain (25 kD) and Heavy Chain (50 kD) fragments since Light Chain fragments (smaller-size) suppress the ionization/MS signal of Heavy Chain fragments (larger-size). With IdeS protease digestion, the Light Chain and Heavy Chain are of similar size (about 23-29 kDa) and can be eluted and analyzed at the same time with minimal MS bias against the Heavy Chain.
- the affinity capture LC-MS F(ab′)2 assay allowed for parallel comparison in ADC biotransformations across ADCs with same drugs conjugated to different antibodies.
- This comparative example demonstrates the potential of the IdeS protease digestion, 2nd-generation assay to accommodate low-dose, labile, and complex site-specific ADCs, e.g., TDCs, for more accurate and detailed biotransformation and PK information.
- site-specific ADCs e.g., TDCs
- the method is applicable to a variety of site-specific ADCs with conjugation sites in the Fab region, and to analysis of conventional ADCs via inter-chain disulfide conjugation.
- ADCs ADCs comprising, for example, small molecule payloads that contribute to the protein's absorbance at 280 nm due to the presence of aromatic rings, and particularly when the extinction coefficient of the small molecule at 280 nm and/or its absorbance maximum are unknown.
- the protein concentration was determined independently of the conjugated payload by proteolytic digestion with Immunoglobulin-degrading enzyme of Streptococcus pyrogenes (IdeS), and subsequent LC-MS analysis.
- IdeS Immunoglobulin-degrading enzyme of Streptococcus pyrogenes
- IdeS cleaves human IgGl's with high specificity at a site below the hinge region generating F(ab′)2 and Fc fragments ( FIG. 1 ). These species can be chromatographically separated on reversed-phase ( FIG. 11 ). Non-covalent interactions between the two arms of the Fc are disrupted by the acidity and organic solvent concentration of the mobile phases, resulting in an Fc/2 peak of approximately 25 kD in size.
- the resultant antibody fragment that is free of drug either the Fc/2 or F(ab′)2 fragment peak, can be used to quantitate the protein concentration of the sample.
- TDC antibody drug conjugates
- Antibody-drug conjugates are digested with IdeS and then injected on reversed-phase LC-MS with detection at an absorbance of 280 nm.
- the antibody fragments that contain drug are chromatographically separated from the Fc/2 fragment allowing for the Fc/2 fragment peak area to be used for protein concentration quantitation.
- This value is interpolated using the linear regression of a standard curve of antibody standards digested with IdeS where starting concentration is plotted against Fc/2 peak area ( FIG. 11 ).
- the drug containing Fc/2 fragment is chromatographically separated from the F(ab′)2 fragment allowing for the F(ab′)2 fragment peak area to be used for protein concentration quantitation.
- This value is interpolated using the linear regression of a standard curve of antibody standards digested with IdeS where starting concentration is plotted against F(ab′)2 peak area ( FIG. 11 ).
- Standard curves (Fc/2 peak areas vs. concentration; FIG. 13A ) (F(ab′)2 peak areas vs. concentration; FIG. 13B ) over a range of 0.5-20 mg/ml were generated using trastuzumab digested with IdeS protease.
- Protein concentration of TDCs site-specifically conjugated on the F(ab) can be determined using peak area of the Fc/2 of the TDC ( FIG. 13A ) and the linear regression.
- Traditional ADCs conjugated on inter-chain disulfides can also be characterized using this method as the Fc/2 fragment is also without drug in these conjugates.
- Protein concentration of TDCs site-specifically conjugated on the Fc can be determined using peak area of the F(ab′)2 of the TDC ( FIG. 13B ) and the linear regression.
- THIOMABsTM with 2 engineered cysteine residues per antibody were incubated with a 3-fold molar excess of a thiol reactive linker-drug at pH 7.5 for 2 hours. Excess linker-drug was purified away by cation exchange and conjugates were formulated into a pH 5.5 buffer.
- the drug to antibody ratio (DAR) of the TDC was determined by LC-MS analysis using the abundance of the deconvoluted masses of drugged and un-drugged species ( FIG. 12 ). All conjugates examined had a DAR of ⁇ 1.7.
- Linker-drug payloads ranged from 700-1500 Da in size.
- IdeS Thirty units (30 unit/ ⁇ l) of IdeS (FABRICATORTM, Genovis AB) were added to 10 ⁇ l of antibody or antibody-drug conjugate that ranged in concentration from 0.52-20 mg/ml. The reaction mixtures were brought to a final volume of 50 ⁇ l with PBS with a final reaction pH of about pH 6.5. Samples where incubated at 37° C. for 1 hr before LC-MS analysis. Samples were analyzed on reversed phase high performance liquid chromatography (HPLC) using an HPLC system (Agilent 1260 infinity) coupled to an electrospray ionization time-of-flight mass spectrometer (Agilent 6224 TOF-LC).
- HPLC reversed phase high performance liquid chromatography
- a volume of 10 ⁇ l of sample was injected on a PLRP-S 1000A°, 8 ⁇ m 50 ⁇ 2.1 mm column (Agilent) heated to 80° C.
- the gradient was generated using 0.05% trifluoroacetic acid (mobile phase A) and 0.05% trifluoroacetic acid in acetonitrile (mobile phase B) at a flow rate of 0.5 ml/min.
- the column was held at 5% B for 0.7 min, followed by a 4.3 min gradient from 30% B to 40% B. At 5 min, the concentration increased to 90% B where it was held for 1 min.
- the column was then re-equilibrated in 5% B for 2 min. Data was acquired and analyzed using Agilent MassHunter software.
- Trastuzumab was serially diluted by a factor of 1.5 from 20 mg/ml to 0.52 mg/ml in 20 mM histidine acetate pH 5.5, 240 mM sucrose. This buffer was chosen for dilutions as it is the buffer used for final formulation of many ADCs and mimics the conditions of an experimental sample in the assay. Samples were diluted in triplicate to a total of ten concentrations.
- a volume of 10 ⁇ l of each dilution was added to 39 ⁇ l of phosphate buffered saline pH 7.2, and 1 ⁇ l of IdeS (30 units/ ⁇ l) to a total volume of 50 ⁇ l. The final pH of these samples was in the optimal activity range for IdeS activity. Samples where incubated at 37° C. for 1 hour. Samples were then run on LC-MS in order or increasing concentration. A volume of 10 ⁇ l of the antibody digests where injected onto a reversed phase column and gradient eluted to separate Fc/2 and F(ab′)2 peaks. Samples that resulted in an injection of >5 ⁇ g of antibody where followed by blank runs of the same LC-MS method with no injection to ensure there was no sample carry-over to the next run.
- Protein concentrations of antibody-drug conjugates were determined by proteolytic digestion with IdeS, and subsequent LC-MS analysis.
- a standard curve was developed using trastuzumab, digested with IdeS at known concentrations ranging from 0.52 mg/ml to 20 mg/ml ( FIGS. 14-16 ).
- the protein concentration of 81 TDCs was determined using this method as well as by the BCA, which is a widely accepted colorimetric assay for protein concentration determination.
- the concentration values determined by each method were plotted against each other showing a strong correlation, validating the accuracy and reproducibility of the IdeS digestion method ( FIG. 17 ).
- the concentration values determined by this method can then be used to calculate the extinction coefficient of the TDC or ADC at an absorbance of A280 using the Beer-Lambert law.
- Human plasma (100 ⁇ L) containing spiked TDC standard mixture was used for the affinity capture and 5 ⁇ L eluent was injected for LC-MS analysis.
- TDC2 anthracycline
- TDC5 CBI dimer
- the assays of the invention include a relatively fast digestion step and continues to completion, without over-digestion.
- this methodology has significant advantages over the use of conventional proteases such as pepsin, papain, and endopeptidase Lysine C.
- pepsin digestion of IgG1s is slow and occurs best below pH 5.
- Papain digestions are performed at neutral pH and the site of protein cleavage is not specific, and often leads to multiple protein cleavage events. Limited LysC digestion may over-digest the Fc region.
- IdeS has no risk of over-digestion as it cleaves IgG1 antibodies at one specific site on the heavy chain below the hinge region. In solution, IdeS is stable at 4° C. for up to one month. These characteristics contribute to the robust protein concentration assay demonstrated here.
- the method can be conducted on HPLC without a mass spectrometer in-line.
- a trastuzumab standard is digested and analyzed alongside test samples for quality control. Complete digestion can be confirmed in this assay as intact antibody has a known retention time and can be detected without mass spectral analysis. The peak area of the absorbance at 280 nm is then correlated directly with protein concentration, without the need for MS analysis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/606,304 US20170370906A1 (en) | 2016-05-27 | 2017-05-26 | Bioanalytical analysis of site-specific antibody drug conjugates |
US16/883,152 US11860156B2 (en) | 2016-05-27 | 2020-05-26 | Bioanalytical analysis of site-specific antibody drug conjugates |
US18/514,615 US20240110909A1 (en) | 2016-05-27 | 2023-11-20 | Bioanalytical analysis of site-specific antibody drug conjugates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662342825P | 2016-05-27 | 2016-05-27 | |
US15/606,304 US20170370906A1 (en) | 2016-05-27 | 2017-05-26 | Bioanalytical analysis of site-specific antibody drug conjugates |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/883,152 Continuation US11860156B2 (en) | 2016-05-27 | 2020-05-26 | Bioanalytical analysis of site-specific antibody drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170370906A1 true US20170370906A1 (en) | 2017-12-28 |
Family
ID=59227890
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/606,304 Abandoned US20170370906A1 (en) | 2016-05-27 | 2017-05-26 | Bioanalytical analysis of site-specific antibody drug conjugates |
US16/883,152 Active 2038-10-27 US11860156B2 (en) | 2016-05-27 | 2020-05-26 | Bioanalytical analysis of site-specific antibody drug conjugates |
US18/514,615 Pending US20240110909A1 (en) | 2016-05-27 | 2023-11-20 | Bioanalytical analysis of site-specific antibody drug conjugates |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/883,152 Active 2038-10-27 US11860156B2 (en) | 2016-05-27 | 2020-05-26 | Bioanalytical analysis of site-specific antibody drug conjugates |
US18/514,615 Pending US20240110909A1 (en) | 2016-05-27 | 2023-11-20 | Bioanalytical analysis of site-specific antibody drug conjugates |
Country Status (5)
Country | Link |
---|---|
US (3) | US20170370906A1 (zh) |
EP (1) | EP3465221B1 (zh) |
JP (1) | JP7022080B2 (zh) |
CN (1) | CN109313200B (zh) |
WO (1) | WO2017205741A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200369720A1 (en) * | 2019-05-23 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Characterization of domain-specific charge variants of antibodies |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
US20210387177A1 (en) * | 2020-06-12 | 2021-12-16 | Waters Technologies Corporation | Desalting devices and pressure-resistant sizing media |
CN114088852A (zh) * | 2020-08-24 | 2022-02-25 | 上海复旦张江生物医药股份有限公司 | 非变性质谱的分析方法及其装置 |
US11779649B2 (en) | 2018-12-21 | 2023-10-10 | Novartis Ag | Antibodies to PMEL17 and conjugates thereof |
US11860156B2 (en) | 2016-05-27 | 2024-01-02 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019229058A1 (en) * | 2018-05-29 | 2019-12-05 | Capsenze Biosystems Ab | Method and system for providing antibody fragments suitable for online quality control |
CN110726784A (zh) * | 2019-10-24 | 2020-01-24 | 乐山师范学院 | 一种提高回收率的鸡粪抗生素提取和净化方法 |
EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc. | PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY |
CN117255808B (zh) * | 2021-01-18 | 2024-06-07 | 上海药明合联生物技术有限公司 | 工程化抗体和包含工程化抗体的抗体-药物偶联物 |
WO2024092073A1 (en) * | 2022-10-26 | 2024-05-02 | Abbratech Inc. | Chimeric antibodies and methods of making and using same |
CN117169317B (zh) * | 2023-10-30 | 2024-01-19 | 内蒙古蒙牛乳业(集团)股份有限公司 | 一种α-s1酪蛋白磷酸化程度检测方法、样品缓冲液及其应用 |
Family Cites Families (401)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US633410A (en) | 1898-09-22 | 1899-09-19 | George A Ames | Ice-cutter. |
US798959A (en) | 1904-12-19 | 1905-09-05 | George W Goss | Corn-husker. |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
CA2023779A1 (en) | 1989-08-23 | 1991-02-24 | Margaret D. Moore | Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH053790A (ja) | 1990-04-19 | 1993-01-14 | Fujisawa Pharmaceut Co Ltd | デヒドロペプチダーゼ−i |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992007574A1 (en) | 1990-10-25 | 1992-05-14 | Tanox Biosystems, Inc. | Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on b cells |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1992017497A1 (en) | 1991-03-29 | 1992-10-15 | Genentech, Inc. | Human pf4a receptors and their use |
US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
US5543503A (en) | 1991-03-29 | 1996-08-06 | Genentech Inc. | Antibodies to human IL-8 type A receptor |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
JP3050424B2 (ja) | 1991-07-12 | 2000-06-12 | 塩野義製薬株式会社 | ヒトエンドセリンリセプター |
US5264557A (en) | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US6153408A (en) | 1991-11-15 | 2000-11-28 | Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale | Altered major histocompatibility complex (MHC) determinant and methods of using the determinant |
US6011146A (en) | 1991-11-15 | 2000-01-04 | Institut Pasteur | Altered major histocompatibility complex (MHC) determinant and methods of using the determinant |
CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
IL107366A (en) | 1992-10-23 | 2003-03-12 | Chugai Pharmaceutical Co Ltd | Genes coding for megakaryocyte potentiator |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5644033A (en) | 1992-12-22 | 1997-07-01 | Health Research, Inc. | Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5869445A (en) | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5773223A (en) | 1993-09-02 | 1998-06-30 | Chiron Corporation | Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof |
EP0731106B1 (en) | 1993-10-01 | 2004-11-17 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin derivatives |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5750370A (en) | 1995-06-06 | 1998-05-12 | Human Genome Sciences, Inc. | Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
US20020193567A1 (en) | 1995-08-11 | 2002-12-19 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
JP3646191B2 (ja) | 1996-03-19 | 2005-05-11 | 大塚製薬株式会社 | ヒト遺伝子 |
CA2254843A1 (en) | 1996-05-17 | 1997-11-27 | Schering Corporation | Human b-cell antigens, related reagents |
US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
US7033827B2 (en) | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
US20030185830A1 (en) | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
EP2343085B1 (en) | 1997-03-10 | 2014-12-10 | The Regents of The University of California | Antibody against prostate stem cell antigen (PSCA) |
US6261791B1 (en) | 1997-03-10 | 2001-07-17 | The Regents Of The University Of California | Method for diagnosing cancer using specific PSCA antibodies |
US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
US6319688B1 (en) | 1997-04-28 | 2001-11-20 | Smithkline Beecham Corporation | Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1) |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
WO1998051824A1 (en) | 1997-05-15 | 1998-11-19 | Abbott Laboratories | Reagents and methods useful for detecting disease of the urinary tract |
US6890749B2 (en) | 1997-05-15 | 2005-05-10 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US20030060612A1 (en) | 1997-10-28 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US20020034749A1 (en) | 1997-11-18 | 2002-03-21 | Billing-Medel Patricia A. | Reagents and methods useful for detecting diseases of the breast |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
US6110695A (en) | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
WO2004031238A2 (en) | 2002-10-03 | 2004-04-15 | Mcgill Univeristy | Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics |
DE69939527D1 (de) | 1998-03-13 | 2008-10-23 | Burnham Inst | Zielsuchende verbindungen für verschiedene organe und gewebe |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
AU4078599A (en) | 1998-05-13 | 1999-11-29 | Epimmune, Inc. | Expression vectors for stimulating an immune response and methods of using the same |
US20020187472A1 (en) | 2001-03-09 | 2002-12-12 | Preeti Lal | Steap-related protein |
US20030064397A1 (en) | 1998-05-22 | 2003-04-03 | Incyte Genomics, Inc. | Transmembrane protein differentially expressed in prostate and lung tumors |
PT1413582E (pt) | 1998-08-27 | 2006-07-31 | Spirogen Ltd | Pirrolobenzodiazepinas dimericas |
WO2000012130A1 (en) | 1998-08-27 | 2000-03-09 | Smithkline Beecham Corporation | Rp105 agonists and antagonists |
GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
JP4689781B2 (ja) | 1998-09-03 | 2011-05-25 | 独立行政法人科学技術振興機構 | アミノ酸輸送蛋白及びその遺伝子 |
AU5963699A (en) | 1998-10-02 | 2000-04-26 | Mcmaster University | Spliced form of (erb)b-2/neu oncogene |
WO2001057188A2 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US6858710B2 (en) | 1998-12-17 | 2005-02-22 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6962980B2 (en) | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
US20030091580A1 (en) | 2001-06-18 | 2003-05-15 | Mitcham Jennifer L. | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20030190669A1 (en) | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000040614A2 (en) | 1998-12-30 | 2000-07-13 | Beth Israel Deaconess Medical Center, Inc. | Characterization of the soc/crac calcium channel protein family |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
WO2000044899A1 (en) | 1999-01-29 | 2000-08-03 | Corixa Corporation | Her-2/neu fusion proteins |
GB9905124D0 (en) | 1999-03-05 | 1999-04-28 | Smithkline Beecham Biolog | Novel compounds |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
US7304126B2 (en) | 1999-05-11 | 2007-12-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU4843500A (en) | 1999-05-14 | 2000-12-05 | Waters Investments Limited | Destructible surfactants and uses thereof |
AU4952600A (en) | 1999-06-03 | 2000-12-28 | Takeda Chemical Industries Ltd. | Screening method with the use of cd100 |
MXPA01013240A (es) | 1999-06-25 | 2002-06-21 | Genentech Inc | Metodo de tratamiento utilizando conjugados de anticuerpo contra erbb-maytansionoide. |
US7589172B2 (en) | 1999-07-20 | 2009-09-15 | Genentech, Inc. | PRO256 polypeptides |
US7297770B2 (en) | 1999-08-10 | 2007-11-20 | Genentech, Inc. | PRO6496 polypeptides |
US7294696B2 (en) | 1999-08-17 | 2007-11-13 | Genentech Inc. | PRO7168 polypeptides |
CA2380355A1 (en) | 1999-09-01 | 2001-03-08 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030129192A1 (en) | 1999-09-10 | 2003-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20030232056A1 (en) | 1999-09-10 | 2003-12-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20030206918A1 (en) | 1999-09-10 | 2003-11-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
US6750054B2 (en) | 2000-05-18 | 2004-06-15 | Lexicon Genetics Incorporated | Human semaphorin homologs and polynucleotides encoding the same |
DE60039448D1 (de) | 1999-10-29 | 2008-08-21 | Genentech Inc | Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung |
EP2363403B1 (en) | 1999-11-29 | 2016-04-20 | The Trustees of Columbia University in the City of New York | Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
EP1248800A2 (en) | 1999-11-30 | 2002-10-16 | Corixa Corporation | Compositions and methods for therapy and diagnosis of breast cancer |
EP1239866A4 (en) | 1999-12-10 | 2005-02-09 | Epimmune Inc | INDUCTION OF HER2 / NEU CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS |
US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
EP1616575B1 (en) | 1999-12-23 | 2012-06-06 | ZymoGenetics, Inc. | Method for treating inflammation |
US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
JP4741139B2 (ja) | 1999-12-23 | 2011-08-03 | ザイモジェネティクス, インコーポレイテッド | 可溶性インターロイキン−20レセプター |
NZ502058A (en) | 1999-12-23 | 2003-11-28 | Ovita Ltd | Isolated mutated nucleic acid molecule for regulation of ovulation rate |
JP2003518075A (ja) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
ATE344801T1 (de) | 1999-12-29 | 2006-11-15 | Immunogen Inc | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
US7297333B2 (en) | 2000-01-20 | 2007-11-20 | Genentech, Inc. | Anti-PRO10268 antibodies |
US20030224379A1 (en) | 2000-01-21 | 2003-12-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
US20020039573A1 (en) | 2000-01-21 | 2002-04-04 | Cheever Martin A. | Compounds and methods for prevention and treatment of HER-2/neu associated malignancies |
US20030104562A1 (en) | 2000-02-11 | 2003-06-05 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030219806A1 (en) | 2000-02-22 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor |
AU2001238596A1 (en) | 2000-02-22 | 2001-09-03 | Millennium Pharmaceuticals, Inc. | 18607, a novel human calcium channel |
US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
WO2001066689A2 (en) | 2000-03-07 | 2001-09-13 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
CA2403637A1 (en) | 2000-03-24 | 2001-10-04 | Fahri Saatcioglu | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
WO2001072830A2 (de) | 2000-03-31 | 2001-10-04 | Ipf Pharmaceuticals Gmbh | Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion |
AU2001253140A1 (en) | 2000-04-03 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tumor markers in ovarian cancer |
NZ521158A (en) | 2000-04-07 | 2004-08-27 | Arena Pharm Inc | Non-endogenous, constitutively activated known G protein-coupled receptors |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2001090304A2 (en) | 2000-05-19 | 2001-11-29 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
WO2001094641A2 (en) | 2000-06-09 | 2001-12-13 | Idec Pharmaceuticals Corporation | Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas |
JP2004523203A (ja) | 2000-06-16 | 2004-08-05 | インサイト・ゲノミックス・インコーポレイテッド | Gタンパク質結合受容体 |
EP1294885A2 (en) | 2000-06-30 | 2003-03-26 | Amgen, Inc. | B7-like molecules and uses thereof |
WO2002002634A2 (en) | 2000-06-30 | 2002-01-10 | Incyte Genomics, Inc. | Human extracellular matrix and cell adhesion polypeptides |
EP1301524A1 (en) | 2000-06-30 | 2003-04-16 | Human Genome Sciences, Inc. | B7-like polynucleotides, polypeptides, and antibodies |
WO2002006339A2 (en) | 2000-07-03 | 2002-01-24 | Curagen Corporation | Proteins and nucleic acids encoding same |
US20040044179A1 (en) | 2000-07-25 | 2004-03-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2002010187A1 (en) | 2000-07-27 | 2002-02-07 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
JP2004505617A (ja) | 2000-07-28 | 2004-02-26 | ヴィッセンバッハ,ウルリヒ | Trp8、Trp9およびTrp10、癌の新規マーカー |
US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
CA2419533A1 (en) | 2000-08-14 | 2002-02-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies |
AU2001283360A1 (en) | 2000-08-14 | 2002-02-25 | Corixa Corporation | Methods for diagnosis and therapy of hematological and virus-associated malignancies |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
CA2420140A1 (en) | 2000-08-24 | 2002-02-28 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
WO2002022660A2 (en) | 2000-09-11 | 2002-03-21 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US6613567B1 (en) | 2000-09-15 | 2003-09-02 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Her-2 expression |
EP1803733B1 (en) | 2000-09-15 | 2010-03-10 | ZymoGenetics, Inc. | Polypeptides comprising the extracellular domains of IL-20RA and/or IL-20RB |
US7491797B2 (en) | 2000-09-15 | 2009-02-17 | Genentech, Inc. | PRO6308 polypeptide |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
CA2422814A1 (en) | 2000-09-18 | 2002-03-21 | Biogen, Inc. | Cripto mutant and uses thereof |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
EP1474528A4 (en) | 2000-10-13 | 2006-06-14 | Protein Design Labs Inc | METHODS FOR DIAGNOSING PROSTATE CANCER, COMPOSITIONS AND METHODS FOR SCREENING PROSTATE CANCER MODULATORS |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
ATE432986T1 (de) | 2000-11-07 | 2009-06-15 | Zymogenetics Inc | Menschlicher rezeptor für tumor necrosis factor |
US20020150573A1 (en) | 2000-11-10 | 2002-10-17 | The Rockefeller University | Anti-Igalpha-Igbeta antibody for lymphoma therapy |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
WO2002054940A2 (en) | 2001-01-12 | 2002-07-18 | University Of Medicine & Dentistry Of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
US20030119133A1 (en) | 2001-01-16 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030119125A1 (en) | 2001-01-16 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
MXPA03006617A (es) | 2001-01-24 | 2004-12-02 | Protein Design Labs Inc | Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho. |
US20030073144A1 (en) | 2001-01-30 | 2003-04-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
WO2002064780A1 (en) | 2001-02-12 | 2002-08-22 | Bionomics Limited | Dna sequences for human tumour suppressor genes |
AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
US6820011B2 (en) | 2001-04-11 | 2004-11-16 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
JP5232350B2 (ja) | 2001-04-17 | 2013-07-10 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | Ca125遺伝子のリピート配列並びに診断および治療的介入のためのその使用 |
AU2002309583A1 (en) | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
CN100352501C (zh) | 2001-04-26 | 2007-12-05 | 比奥根艾迪克Ma公司 | Cripto阻断抗体及其用途 |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
JP2005504513A (ja) | 2001-05-09 | 2005-02-17 | コリクサ コーポレイション | 前立腺癌の治療及び診断のための組成物及び方法 |
AU2002344326A1 (en) | 2001-05-11 | 2002-11-25 | Sloan-Kettering Institute For Cancer Research | Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof |
KR20040030628A (ko) | 2001-05-24 | 2004-04-09 | 지모제넥틱스, 인코포레이티드 | Taci-면역글로불린 융합 단백질 |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US7157558B2 (en) | 2001-06-01 | 2007-01-02 | Genentech, Inc. | Polypeptide encoded by a polynucleotide overexpresses in tumors |
JP2005518185A (ja) | 2001-06-04 | 2005-06-23 | キュラジェン コーポレイション | 新規タンパク質およびそれをコード化する核酸 |
WO2002098358A2 (en) | 2001-06-04 | 2002-12-12 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
WO2002099040A2 (en) | 2001-06-05 | 2002-12-12 | Exelixis, Inc. | Igs as modifiers of the p53 pathway and methods of use |
CA2449289A1 (en) | 2001-06-05 | 2002-12-12 | Exelixis, Inc. | Gfats as modifiers of the p53 pathway and methods of use |
US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
US7125663B2 (en) | 2001-06-13 | 2006-10-24 | Millenium Pharmaceuticals, Inc. | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
WO2002102235A2 (en) | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
WO2003002717A2 (en) | 2001-06-28 | 2003-01-09 | Schering Corporation | Biological activity of ak155 |
WO2003004529A2 (en) | 2001-07-02 | 2003-01-16 | Licentia Ltd. | Ephrin-tie receptor materials and methods |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
WO2003003984A2 (en) | 2001-07-05 | 2003-01-16 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
US7446185B2 (en) | 2001-07-18 | 2008-11-04 | The Regents Of The University Of California | Her2/neu target antigen and use of same to stimulate an immune response |
WO2003009814A2 (en) | 2001-07-25 | 2003-02-06 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
PL377119A1 (pl) | 2001-08-03 | 2006-01-23 | Genentech, Inc. | Peptydy TACIs i BR3 i ich zastosowanie |
CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US20070015145A1 (en) | 2001-08-14 | 2007-01-18 | Clifford Woolf | Nucleic acid and amino acid sequences involved in pain |
US20030092013A1 (en) | 2001-08-16 | 2003-05-15 | Vitivity, Inc. | Diagnosis and treatment of vascular disease |
AU2002313559A1 (en) | 2001-08-23 | 2003-03-10 | Oxford Biomedica (Uk) Limited | Genes |
AU2002357643A1 (en) | 2001-08-29 | 2003-04-14 | Vanderbilt University | The human mob-5 (il-24) receptors and uses thereof |
US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
ES2537074T3 (es) | 2001-09-06 | 2015-06-02 | Agensys, Inc. | Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer |
AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
NZ531674A (en) | 2001-09-18 | 2009-03-31 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
WO2003025228A1 (en) | 2001-09-18 | 2003-03-27 | Proteologics, Inc. | Methods and compositions for treating hcap associated diseases |
WO2003025148A2 (en) | 2001-09-19 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
US20030077644A1 (en) | 2001-09-28 | 2003-04-24 | Bing Yang | Diagnosis and treatment of diseases caused by mutations in CD72 |
AU2002362436A1 (en) | 2001-10-03 | 2003-04-14 | Rigel Pharmaceuticals, Inc. | Modulators of lymphocyte activation and migration |
AU2002362454A1 (en) | 2001-10-03 | 2003-04-14 | Origene Technologies, Inc. | Regulated breast cancer genes |
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2002351505B2 (en) | 2001-10-19 | 2008-04-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
WO2003035846A2 (en) | 2001-10-24 | 2003-05-01 | National Jewish Medical And Research Center | Structure of tall-1 and its cognate receptor |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
BR0213738A (pt) | 2001-10-31 | 2006-11-21 | Alcon Inc | proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucoma |
US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2003045422A1 (en) | 2001-11-29 | 2003-06-05 | Genset S.A. | Agonists and antagonists of prolixin for the treatment of metabolic disorders |
WO2003048202A2 (en) | 2001-12-03 | 2003-06-12 | Asahi Kasei Pharma Corporation | Nf-kappab activating genes |
AU2002366951A1 (en) | 2001-12-10 | 2003-07-09 | Nuvelo,Inc. | Novel nucleic acids and polypeptides |
GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20030134790A1 (en) | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
US7452675B2 (en) | 2002-01-25 | 2008-11-18 | The Queen's Medical Center | Methods of screening for TRPM4b modulators |
WO2003072736A2 (en) | 2002-02-21 | 2003-09-04 | Duke University | Reagents and treatment methods for autoimmune diseases |
WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2003083047A2 (en) | 2002-03-01 | 2003-10-09 | Exelixis, Inc. | MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
WO2003101400A2 (en) | 2002-06-04 | 2003-12-11 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
WO2003104399A2 (en) | 2002-06-07 | 2003-12-18 | Avalon Pharmaceuticals, Inc | Cancer-linked gene as target for chemotherapy |
EP2258712A3 (en) | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
WO2004000997A2 (en) | 2002-03-19 | 2003-12-31 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
CA2478981A1 (en) | 2002-03-21 | 2003-10-02 | Sunesis Pharmaceuticals, Inc. | Identification of kinase inhibitors |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
EP1494693B1 (en) | 2002-03-22 | 2010-12-08 | Biogen Idec MA Inc. | Cripto-specific antibodies |
JP2005521429A (ja) | 2002-03-25 | 2005-07-21 | ユーエービー リサーチ ファウンデーション | Fcレセプターホモログ、試薬およびこれらの使用 |
WO2003083074A2 (en) | 2002-03-28 | 2003-10-09 | Idec Pharmaceuticals Corporation | Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas |
US20030194704A1 (en) | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
CA2481503A1 (en) | 2002-04-05 | 2003-10-23 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
WO2003084570A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
WO2003087768A2 (en) | 2002-04-12 | 2003-10-23 | Mitokor | Targets for therapeutic intervention identified in the mitochondrial proteome |
CA2481507A1 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20030224467A1 (en) | 2002-04-17 | 2003-12-04 | Osborne C. Kent | AIB1 as a prognostic marker and predictor of resistance to endocrine therapy |
AU2003228869A1 (en) | 2002-05-03 | 2003-11-17 | Incyte Corporation | Transporters and ion channels |
AU2003229294A1 (en) | 2002-05-15 | 2003-12-02 | Avalon Pharmaceuticals | Cancer-linked gene as target for chemotherapy |
WO2003101388A2 (en) | 2002-05-30 | 2003-12-11 | Bristol-Myers Squibb Company | Human solute carrier family 7 member 11 (hslc7a11) |
US8580533B2 (en) | 2002-05-31 | 2013-11-12 | Waters Technologies Corporation | Destructible surfactants and uses thereof |
EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2003101283A2 (en) | 2002-06-04 | 2003-12-11 | Incyte Corporation | Diagnostics markers for lung cancer |
AU2003242633A1 (en) | 2002-06-06 | 2003-12-22 | Molecular Engines Laboratories | Dudulin genes, non-human animal model: uses in human hematological disease |
CN100532549C (zh) | 2002-06-06 | 2009-08-26 | 肿瘤疗法科学股份有限公司 | 与人结肠癌相关的基因和多肽 |
AU2003245441A1 (en) | 2002-06-12 | 2003-12-31 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
US20040249130A1 (en) | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
US20040022727A1 (en) | 2002-06-18 | 2004-02-05 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
AU2003245615A1 (en) | 2002-06-20 | 2004-01-06 | The Regents Of The University Of California | Compositions and methods for modulating lymphocyte activity |
EP2365004B1 (en) | 2002-06-21 | 2016-01-06 | Johns Hopkins University School of Medicine | Membrane associated tumor endothelium markers |
WO2004009622A2 (en) | 2002-07-19 | 2004-01-29 | Cellzome Ag | Protein complexes of cellular networks underlying the development of cancer and other diseases |
AU2003256836A1 (en) | 2002-07-25 | 2004-02-16 | Genentech, Inc. | Taci antibodies and uses thereof |
AU2003263964C1 (en) | 2002-07-31 | 2010-08-19 | Seagen Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
AU2003251471A1 (en) | 2002-08-06 | 2004-02-25 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5) |
JP2004121218A (ja) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
AU2003259163B2 (en) | 2002-08-16 | 2008-07-03 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
CA2495389A1 (en) | 2002-08-19 | 2004-02-26 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2003278725A1 (en) | 2002-08-27 | 2004-03-19 | Bristol-Myers Squibb Company | Polynucleotide predictor set for identifying protein tyrosine kinase modulators |
WO2004020595A2 (en) | 2002-08-29 | 2004-03-11 | Five Prime Therapeutics, Inc. | Novel human polypeptides encoded by polynucleotides |
AU2002951346A0 (en) | 2002-09-05 | 2002-09-26 | Garvan Institute Of Medical Research | Diagnosis of ovarian cancer |
JP2005537800A (ja) | 2002-09-06 | 2005-12-15 | マンカインド コーポレイション | エピトープ配列 |
AU2003300776A1 (en) | 2002-09-09 | 2004-05-25 | Omeros Corporation | G protein coupled receptors and uses thereof |
JP2004113151A (ja) | 2002-09-27 | 2004-04-15 | Sankyo Co Ltd | 癌遺伝子及びその用途 |
AU2003288918A1 (en) | 2002-10-04 | 2004-05-04 | Van Andel Research Institute | Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1581169A4 (en) | 2002-11-08 | 2008-09-17 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO NATURAL K CELLS |
CA2503621A1 (en) | 2002-11-13 | 2004-05-27 | Genentech, Inc. | Methods and compositions for diagnosing dysplasia |
WO2004045553A2 (en) | 2002-11-15 | 2004-06-03 | The Board Of Trustees Of The University Of Arkansas | Ca125 gene and its use for diagnostic and therapeutic interventions |
AU2003298650B2 (en) | 2002-11-15 | 2010-03-11 | Musc Foundation For Research Development | Complement receptor 2 targeted complement modulators |
AU2003297300A1 (en) | 2002-11-20 | 2004-06-15 | Biogen Idec Inc. | Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas |
EP2410332A1 (en) | 2002-11-21 | 2012-01-25 | The University Of Utah | Method for identifying purinergic modulators of the olfactory system |
US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
AU2003302774A1 (en) | 2002-12-06 | 2004-06-30 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific genes and proteins |
US20040157278A1 (en) | 2002-12-13 | 2004-08-12 | Bayer Corporation | Detection methods using TIMP 1 |
TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
CA2510315C (en) | 2002-12-20 | 2014-01-28 | Protein Design Labs, Inc. | Antibodies against gpr64 and uses thereof |
AU2003299819A1 (en) | 2002-12-23 | 2004-07-22 | Human Genome Sciences, Inc. | Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof |
WO2004063709A2 (en) | 2003-01-08 | 2004-07-29 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
US20050227301A1 (en) | 2003-01-10 | 2005-10-13 | Polgen | Cell cycle progression proteins |
WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
US20040171823A1 (en) | 2003-01-14 | 2004-09-02 | Nadler Steven G. | Polynucleotides and polypeptides associated with the NF-kappaB pathway |
JP2007520996A (ja) | 2003-01-15 | 2007-08-02 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 44390、54181、211、5687、884、1405、636、4421、5410、30905、2045、16405、18560、2047、33751、52872、14063、20739、32544、43239、44373、51164、53010、16852、1587、2207、22245、2387、52908、69112、14990、18547、115、579、15985、15625、760、18603、2395、2554、8675、32720、4809、14303、16816、17827、32620、577、619、1423、2158、8263、15402、16209、16386、21165、30911、41897、1643、2543、9626、13231、32409、84260、2882、8203、32678または55053を用いて泌尿器科障害を処置するための方法および組成物 |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
CA2516128A1 (en) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
US20030224411A1 (en) | 2003-03-13 | 2003-12-04 | Stanton Lawrence W. | Genes that are up- or down-regulated during differentiation of human embryonic stem cells |
DE60326060D1 (de) | 2003-03-31 | 2009-03-19 | Council Scient Ind Res | Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung |
US7755007B2 (en) | 2003-04-17 | 2010-07-13 | K&H Manufacturing, Inc | Heated pet mat |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
ATE516288T1 (de) | 2003-10-22 | 2011-07-15 | Us Gov Health & Human Serv | Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
SI1725249T1 (sl) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Spojine monometilvalina, sposobne konjugacije na ligande |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
JP5166861B2 (ja) | 2004-03-09 | 2013-03-21 | スピロゲン リミティッド | ピロロベンゾジアゼピン |
AU2005230848B9 (en) | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
WO2005101017A1 (en) | 2004-04-07 | 2005-10-27 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
EP2286844A3 (en) | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antibody-drug conjugates and methods |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP3498289A1 (en) | 2005-07-07 | 2019-06-19 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
ES2673822T3 (es) | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
ES2374403T3 (es) | 2006-12-21 | 2012-02-16 | Novartis Ag | Cuantificación de anticuerpos. |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
ES2435779T3 (es) | 2007-07-19 | 2013-12-23 | Sanofi | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico |
WO2009052249A1 (en) | 2007-10-19 | 2009-04-23 | Genentech, Inc. | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
EP2225273B1 (en) * | 2007-12-21 | 2012-05-23 | Roche Glycart AG | Stability testing of antibodies |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
WO2009099741A1 (en) | 2008-02-01 | 2009-08-13 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
EP2277044B1 (en) * | 2008-05-13 | 2015-06-17 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
US20110151494A1 (en) | 2008-06-30 | 2011-06-23 | H. Lee Moffit Cancer & Research Institute | Methods and materials for monitoring myeloma using quantitative mass spectrometry |
ES2532635T3 (es) | 2008-07-15 | 2015-03-30 | Genentech, Inc. | Conjugados de antraciclina, proceso para su preparación y su uso como compuestos antitumorales |
EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
IL271761B (en) | 2009-02-05 | 2022-09-01 | Immunogen Inc | (12as)-8-methoxy-9-benzyloxy-11,12,12a,13-tetrahydro-6h-indolo[2,1-c][1,4]benzodiazepine-6-one, 4-benzyloxy-5-methoxy -2-nitrobenzoic acid and a process for their preparation |
EP3485912A1 (en) | 2009-04-08 | 2019-05-22 | Faulstich, Heinz, Dr. | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
US20120264155A1 (en) | 2009-10-09 | 2012-10-18 | Symphogen A/S | Multiplex Quantitation of Individual Recombinant Proteins in a Mixture by Signature Peptides and Mass Spectrometry |
US8697650B2 (en) | 2010-02-16 | 2014-04-15 | Medimmune, Llc | HSA-related compositions and methods of use |
PE20130342A1 (es) | 2010-04-15 | 2013-04-20 | Spirogen Sarl | Pirrolobenzodiacepinas y conjugados de las mismas |
WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
EP2579897A1 (en) | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
ES2402254T3 (es) | 2010-09-30 | 2013-04-30 | Heidelberg Pharma Ag | Conjugados de amatoxinas con ligadores mejorados |
BR112013019499B1 (pt) | 2011-02-04 | 2023-01-10 | Genentech, Inc. | Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
CA2833212C (en) * | 2011-05-12 | 2020-06-09 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides |
HUE025661T2 (en) | 2011-10-14 | 2016-04-28 | Medimmune Ltd | Pyrrolobenzodiazepines and their conjugates |
MX366864B (es) | 2012-02-27 | 2019-07-26 | Amunix Operating Inc | Composiciones de conjugados de xten y métodos para realizarlas. |
US20150218220A1 (en) | 2012-09-12 | 2015-08-06 | Brian Alan MENDELSOHN | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
EA201690195A1 (ru) | 2013-08-12 | 2016-05-31 | Дженентек, Инк. | Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения |
GB201316744D0 (en) * | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
EP3082875B1 (en) | 2013-12-16 | 2020-11-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
BR112016014126B1 (pt) | 2013-12-16 | 2023-02-14 | Medimmune Limited | Composto não-peptídico, conjugados de anticorpo-fármaco do mesmo, uso dos ditos conjugados para o tratamento de câncer e composição farmacêutica que compreende os mesmos |
CN105873614B (zh) | 2013-12-16 | 2020-10-30 | 基因泰克公司 | 肽模拟化合物及其抗体-药物缀合物 |
US11092574B2 (en) | 2013-12-24 | 2021-08-17 | Waters Technologies Corporation | Materials for hydrophilic interaction chromatography and processes for preparation and use thereof for analysis of glycoproteins and glycopeptides |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
JP6943872B2 (ja) * | 2016-03-25 | 2021-10-06 | ジェネンテック, インコーポレイテッド | 多重全抗体及び抗体複合体化薬物定量化アッセイ |
JP7022080B2 (ja) | 2016-05-27 | 2022-02-17 | ジェネンテック, インコーポレイテッド | 部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法 |
-
2017
- 2017-05-26 JP JP2018562100A patent/JP7022080B2/ja active Active
- 2017-05-26 US US15/606,304 patent/US20170370906A1/en not_active Abandoned
- 2017-05-26 WO PCT/US2017/034680 patent/WO2017205741A1/en unknown
- 2017-05-26 EP EP17733651.8A patent/EP3465221B1/en active Active
- 2017-05-26 CN CN201780026939.7A patent/CN109313200B/zh active Active
-
2020
- 2020-05-26 US US16/883,152 patent/US11860156B2/en active Active
-
2023
- 2023-11-20 US US18/514,615 patent/US20240110909A1/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11860156B2 (en) | 2016-05-27 | 2024-01-02 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
US11779649B2 (en) | 2018-12-21 | 2023-10-10 | Novartis Ag | Antibodies to PMEL17 and conjugates thereof |
US20200369720A1 (en) * | 2019-05-23 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Characterization of domain-specific charge variants of antibodies |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
US20210387177A1 (en) * | 2020-06-12 | 2021-12-16 | Waters Technologies Corporation | Desalting devices and pressure-resistant sizing media |
CN114088852A (zh) * | 2020-08-24 | 2022-02-25 | 上海复旦张江生物医药股份有限公司 | 非变性质谱的分析方法及其装置 |
Also Published As
Publication number | Publication date |
---|---|
CN109313200A (zh) | 2019-02-05 |
WO2017205741A1 (en) | 2017-11-30 |
JP7022080B2 (ja) | 2022-02-17 |
EP3465221A1 (en) | 2019-04-10 |
JP2019519769A (ja) | 2019-07-11 |
US20210011000A1 (en) | 2021-01-14 |
CN109313200B (zh) | 2022-10-04 |
EP3465221B1 (en) | 2020-07-22 |
US11860156B2 (en) | 2024-01-02 |
US20240110909A1 (en) | 2024-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11860156B2 (en) | Bioanalytical analysis of site-specific antibody drug conjugates | |
US20240012003A1 (en) | Multiplexed total antibody and antibody-conjugated drug quantification assay | |
US10729738B2 (en) | Hindered disulfide drug conjugates | |
JP5987053B2 (ja) | フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングlc−ms/ms法 | |
CN109689111B (zh) | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 | |
US10730900B2 (en) | Calicheamicin-antibody-drug conjugates and methods of use | |
EP3522933B1 (en) | Methods for preparing antibody drug conjugates | |
US20220047711A1 (en) | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |